Salts of pyrrolotriazine derivatives useful as TAM inhibitors

Abstract

To provide compounds for modulation of TAM kinases in treatment of cancer.SOLUTION: The invention provides a salt being N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present disclosure provides salt forms of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which are useful as inhibitors of TAM kinases, as well as methods of manufacture and intermediates related thereto. [Background technology]

[0002] Receptor tyrosine kinases (RTKs) are cell surface proteins that transmit signals from the extracellular environment to the cell cytoplasm and nucleus to control cellular events such as survival, growth, proliferation, differentiation, adhesion, and migration.

[0003] The TAM subfamily consists of three RTKs, including Tyro3, ​​AXL, and Mer (Graham et al., 2014, Nature Reviews Cancer 14, 769-785; Linger et al., 2008, Advances in Cancer Research 100, 35-83). TAM kinases are characterized by an extracellular ligand-binding domain consisting of two immunoglobulin-like domains and two fibronectin type III domains. Two ligands have been identified for TAM kinases: growth arrest specific 6 (GAS6) and protein S (PROS1). GAS6 can bind and activate all three TAM kinases, while PROS1 is a ligand for Mer and Tyro3 (Graham et al., 2014, Nature Reviews Cancer 14, 769-785).

[0004] AXL (also known as UFO, ARK, JTK11, TYRO7) was originally identified as a transforming gene in DNA from patients with chronic myeloid leukemia (O'Bryan et al., 1991, Mol Cell Biol 11, 5016-5031; Graham et al., 2014, Nature Reviews Cancer 14, 769-785; Linger et al., 2008, Advances in Cancer Research 100, 35-83). GAS6 binds to AXL and subsequently induces autophosphorylation and activation of the AXL tyrosine kinase. AXL activates several downstream signaling pathways, including PI3K-Akt, Raf-MAPK, and PLC-PKC (Feneyrolles et al., 2014, Molecular Cancer Therapeutics 13, 2141-2148; Linger et al., 2008, Advances in Cancer Research 100, 35-83).

[0005] MER (also known as MERTK, EYK, RYK, RP38, NYK, and TYRO12) was initially identified as a phosphorylated protein from a lymphoblastoid expression library (Graham et al., 1995, Oncogene 10, 2349-2359; Graham et al., 2014, Nature Reviews Cancer 14, 769-785; Linger et al., 2008, Advances in Cancer Research 100, 35-83). Both GAS6 and PROS1 can bind to Mer and induce phosphorylation and activation of Mer kinase (Lew et al., 2014). MER activation, like AXL, also transduces downstream signaling pathways including PI3K-Akt and Raf-MAPK (Linger et al., 2008, Advances in Cancer Research 100, 35-83).

[0006] TYRO3 (also known as DTK, SKY, RSE, BRT, TIF, ETK2) was initially identified through PCR-based cloning studies (Lai et al., Neuron 6, 691-70, 1991;Graham et al., 2014, Nature Reviews Cancer 14, 769-785;Linger et al., 2008, Advances in Cancer Research 100, 35-83). Both ligands, GAS6 and PROS1, can bind and activate TYRO3. The signaling pathway downstream of TYRO3 activation is the least explored of the TAM RTKs, but appears to involve both the PI3K-Akt and Raf-MAPK pathways (Linger et al., 2008, Advances in Cancer Research 100, 35-83). AXL, MER, and TYRO3 have been found to be overexpressed in cancer cells.

[0007] Thus, there is a need for compounds and methods of their use for modulating TAM kinases in the treatment of cancer. Summary of the Invention

[0008] The present application provides compounds of formula I: [ka] The present invention provides a salt of the compound of the formula:

[0009] The present application further provides a maleate salt of the compound of formula I.

[0010] The present application further provides methods for preparing salts of compounds of formula I.

[0011] The present application provides compounds of formula II: [ka] The present invention provides a salt of the compound of the formula:

[0012] The present application further provides a hemisulfate salt of the compound of formula II.

[0013] The present application further provides a phosphate salt of the compound of formula II.

[0014] The present application further provides a maleate salt of the compound of formula II.

[0015] The present application further provides the hydrochloride salt of the compound of formula II.

[0016] The present application further provides a salicylate salt of the compound of formula II.

[0017] The present application further provides a methanesulfonate salt (ie, a mesylate salt) of the compound of formula II.

[0018] The present application further provides an ethanesulfonate salt (ie, an esylate salt) of the compound of formula II.

[0019] The present application further provides methods for preparing salts of compounds of formula II.

[0020] The present application further provides pharmaceutical compositions comprising any of the above salts of the compounds of Formulas I and II.

[0021] The present application also provides a method of inhibiting a TAM kinase comprising contacting said TAM kinase with any of the above salts of the compounds of Formulas I and II.

[0022] The present application also provides a method of inhibiting AXL kinase and MER kinase, comprising contacting said AXL kinase or MER kinase with any of the above salts of the compounds of Formulas I and II.

[0023] The application also provides a method of treating cancer in a patient comprising administering to said patient a therapeutically effective amount of any of the above salts of the compounds of Formulas I and II. [Brief description of the drawings]

[0024] [Figure 1] FIG. 2 shows an XRPD pattern representing Compound I maleate, Form I. [Diagram 2] FIG. 2 shows a DSC curve representing Compound I maleate, Form I. [Diagram 3] FIG. 2 shows TGA data representing Compound I maleate salt, Form I. [Figure 4] FIG. 2 shows an XRPD pattern representative of Compound II phosphate. [Diagram 5] FIG. 2 shows a DSC curve representing Compound II phosphate. [Figure 6] FIG. 1 shows TGA data representative of Compound II phosphate. [Figure 7] FIG. 2 shows an XRPD pattern representative of Compound II maleate. [Figure 8] FIG. 2 shows a DSC curve representing Compound II maleate salt. [Figure 9] FIG. 1 shows TGA data representative of Compound II maleate salt. [Figure 10] FIG. 2 shows an XRPD pattern representative of Compound II hemisulfate. [Figure 11] FIG. 2 shows a DSC curve representing Compound II hemisulfate. [Figure 12] FIG. 1 shows TGA data representing Compound II hemisulfate. [Figure 13] FIG. 2 shows an XRPD pattern representative of Compound II hydrochloride. [Figure 14] FIG. 2 shows a DSC curve representing Compound II hydrochloride. [Figure 15] FIG. 1 shows TGA data representing Compound II hydrochloride salt. [Figure 16] FIG. 2 shows an XRPD pattern representative of Compound II salicylate. [Figure 17] FIG. 2 shows a DSC curve representing Compound II salicylate. [Figure 18] FIG. 1 shows TGA data representative of Compound II salicylate salt. [Figure 19] FIG. 2 shows an XRPD pattern representative of Compound II methanesulfonate salt. [Figure 20] FIG. 2 shows a DSC curve representing compound II methanesulfonate salt. [Figure 21] FIG. 1 shows TGA data representing Compound II methanesulfonate salt. [Figure 22] FIG. 2 shows an XRPD pattern representative of Compound II ethanesulfonate salt. [Figure 23] FIG. 2 shows a DSC curve representing compound II ethanesulfonate salt. [Figure 24] FIG. 1 shows TGA data representing Compound II ethanesulfonate salt. [Diagram 25] FIG. 2 shows an XRPD pattern representing Compound I maleate salt, Form II. [Figure 26] FIG. 2 shows an XRPD pattern representing Compound I maleate, Form III. [Figure 27] FIG. 2 shows a DSC curve representing Compound I maleate salt, Form III. [Figure 28] FIG. 2 shows TGA data representing Compound I maleate salt, Form III. [Figure 29] FIG. 2 shows an XRPD pattern representing Compound I maleate salt, Form IV. [Diagram 30] FIG. 2 shows a DSC curve representing Compound I maleate salt, Form IV. [Diagram 31] FIG. 1 shows TGA data representing Compound I maleate salt, Form IV. [Diagram 32] FIG. 2 shows an XRPD pattern representative of Compound I maleate, Form V. [Diagram 33] FIG. 2 shows a DSC curve representing Compound I maleate salt, Form V. [Diagram 34] FIG. 2 shows TGA data representing Compound I maleate salt, Form V. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] Compounds and Salts The present application provides compounds of formula I: [ka] or pharma- ceutically acceptable hydrates and solvates thereof.

[0026] Thus, in some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate (also referred to herein as the maleate salt of the compound of Formula I, the maleate salt of Compound I, Compound I maleate salt, or any variation thereof).

[0027] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide to maleic acid.

[0028] Different forms of the same substance have different bulk properties, for example, related to hygroscopicity, solubility, stability, etc. Forms with high melting points often have good thermodynamic stability, which is advantageous for extending the shelf life of formulations containing the solid form. Forms with low melting points often have lower thermodynamic stability, but are advantageous in that they have improved water solubility, leading to improved bioavailability of the drug. Forms with low hygroscopicity are more desirable for their stability against heat and humidity, and are resistant to degradation during long-term storage.

[0029] The solid forms (e.g., crystalline forms) described herein may have certain advantages, for example, the forms may have desirable properties such as ease of handling, ease of processing, storage stability, and ease of purification. Furthermore, the crystalline forms may be useful for improving the performance characteristics of pharmaceutical products, such as dissolution profile, shelf life, and bioavailability.

[0030] In some embodiments, the maleate salt of the compound of formula I provided herein is crystalline.As used herein, "crystalline" or "crystal form" refers to a specific lattice configuration of a crystalline substance.Different crystal forms of the same substance generally have different crystal lattices (e.g., unit cells) due to the different physical properties characteristic of each crystal form.In some cases, different lattice configurations have different water or solvent contents.

[0031] The different salt forms can be identified by solid state characterization techniques such as X-ray powder diffraction (XRPD). Other characterization techniques such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption (DVS) can further help identify the form as well as determine stability and solvent / water content.

[0032] The pattern of XRPD reflections (peaks) is generally considered as a fingerprint of a particular crystal morphology. It is well known that the relative intensity of XRPD peaks can vary widely depending on, among other things, the sample preparation technique, the crystal size distribution, the various filters used, the sample mounting procedure, and the particular instrument used. In some cases, new peaks may be observed or existing peaks may disappear depending on the type or settings of the instrument. As used herein, the term "peak" refers to a reflection having a relative height / intensity of at least about 4% of the maximum peak height / intensity. Furthermore, instrumental differences and other factors may affect the 2θ values. Thus, peak assignments such as those reported herein may vary by plus or minus about 0.2° (2θ), and in the context of XRPD herein, the terms "substantially" and "about" are meant to encompass the above variations.

[0033] Similarly, temperature readings associated with DSC, TGA, or other thermal experiments may vary by about ±3° C. depending on the instrument, the particular settings, sample preparation, etc. Thus, any crystalline form reported herein whose DSC curve is "substantially" depicted in any figure or the term "about" should be understood to take such variations into account.

[0034] In some embodiments, the salts and compounds described herein (e.g., the compound of formula I or the maleate salt of the compound of formula I) are substantially isolated. By "substantially isolated" is meant that the salt or compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation may include, for example, a composition enriched in the salt described herein. Substantial separation may include at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, or at least about 99% by weight of the salt described herein, or a composition containing the salt. Methods for isolating compounds and their salts are conventional in the art.

[0035] The maleate salt of the compound of formula I can be prepared in various crystalline forms, including, for example, Form I, Form II, Form III, Form IV, or Form V.

[0036] The maleate salt of the compound of formula I, Form I: Provided herein are embodiments (i)-(x) of a crystalline form of the compound of Formula I, designated Form I, which crystalline form is described below in Examples 1 and 7.

[0037] (i) In some embodiments, the maleate salt of the compound of formula I has at least one XRPD peak selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°, expressed in terms of 2θ.

[0038] (ii) In some embodiments, the maleate salt of the compound of formula I has at least two XRPD peaks selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5° in terms of 2θ.

[0039] (iii) In some embodiments, the maleate salt of the compound of formula I has at least three XRPD peaks selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5° in terms of 2θ.

[0040] (iv) In some embodiments, the maleate salt of the compound of formula I has at least four XRPD peaks selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5° in terms of 2θ.

[0041] (v) In some embodiments, the maleate salt of the compound of formula I above has the following XRPD peaks, expressed in terms of 2θ: about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

[0042] (vi) In some embodiments, the maleate salt of the compound of formula I above has the following XRPD peaks, expressed in terms of 2θ: about 4.3°, about 8.4°, and about 13.2°.

[0043] (vii) In some embodiments, the maleate salt of the compound of formula I above has an XRPD profile substantially as shown in FIG.

[0044] (viii) In some embodiments, the maleate salt of the compound of formula I has an endothermic peak at about 211° C. in the DSC curve.

[0045] (ix) In some embodiments, the maleate salt of the compound of formula I above has a DSC curve substantially as shown in FIG.

[0046] (x) In some embodiments, the maleate salt of the compound of formula I above has a TGA curve substantially as shown in FIG.

[0047] The maleate salt of the compound of formula I, Form II: Provided herein is a crystalline form of Compound I designated Form II, which is described below in Examples 16 and 17.

[0048] In some embodiments, Form II of the maleate salt of the compound of Formula I above has at least one XRPD peak selected from about 3.8°, about 7.8°, about 23.5°, and about 26.0°, expressed in terms of 2θ.

[0049] In some embodiments, Form II of the maleate salt of the compound of Formula I above has at least two XRPD peaks selected from about 3.8°, about 7.8°, about 23.5°, and about 26.0° in terms of 2θ.

[0050] In some embodiments, Form II of the maleate salt of the compound of Formula I above has at least three XRPD peaks selected from about 3.8°, about 7.8°, about 23.5°, and about 26.0° in terms of 2θ.

[0051] In some embodiments, Form II of the maleate salt of the compound of Formula I above has the following XRPD peaks, expressed in terms of 2θ: about 3.8°, about 7.8°, about 23.5°, and about 26.0°.

[0052] In some embodiments, Form II of the maleate salt of the compound of Formula I above has the following XRPD peaks, expressed in terms of 2θ: about 3.8°, about 7.8°, and about 23.5°.

[0053] In some embodiments, Form II of the maleate salt of the compound of Formula I above has an XRPD profile substantially as shown in FIG.

[0054] The maleate salt of the compound of formula I, Form III: Provided herein is a crystalline form of Compound I designated Form III, which is described below in Examples 16 and 18.

[0055] In some embodiments, Form III of the maleate salt of the compound of Formula I above has at least one XRPD peak selected from about 3.8°, about 7.7°, about 12.1°, about 18.9°, and about 20.6°, expressed in terms of 2θ.

[0056] In some embodiments, Form III of the maleate salt of the compound of Formula I above has at least two XRPD peaks selected from about 3.8°, about 7.7°, about 12.1°, about 18.9°, and about 20.6°, expressed in terms of 2θ.

[0057] In some embodiments, Form III of the maleate salt of the compound of Formula I has at least three XRPD peaks selected from about 3.8°, about 7.7°, about 12.1°, about 18.9°, and about 20.6° in terms of 2θ.

[0058] In some embodiments, Form III of the maleate salt of the compound of Formula I above has at least four XRPD peaks selected from about 3.8°, about 7.7°, about 12.1°, about 18.9°, and about 20.6° in terms of 2θ.

[0059] In some embodiments, Form III of the maleate salt of the compound of Formula I above has the following XRPD peaks, expressed in terms of 2θ: about 3.8°, about 7.7°, about 12.1°, about 18.9°, and about 20.6°.

[0060] In some embodiments, Form III of the maleate salt of the compound of Formula I above has the following XRPD peaks, expressed in terms of 2θ: about 3.8°, about 7.7°, about 12.1°, and about 18.9°.

[0061] In some embodiments, Form III of the maleate salt of the compound of Formula I above has an XRPD profile substantially as shown in FIG.

[0062] In some embodiments, Form III of the maleate salt of the compound of Formula I has endothermic peaks in a DSC curve at about 165.4° C. and about 195.4° C. In some embodiments, Form III of the maleate salt of the compound of Formula I has an endothermic peak in a DSC curve at about 165.4° C. In some embodiments, Form III of the maleate salt of the compound of Formula I has an endothermic peak in a DSC curve at about 195.4° C.

[0063] In some embodiments, Form III of the maleate salt of the compound of Formula I above has a DSC curve substantially as shown in FIG.

[0064] In some embodiments, Form III of the maleate salt of the compound of Formula I above has a TGA curve substantially as shown in FIG.

[0065] The maleate salt of the compound of formula I, Form IV: Provided herein is a crystalline form of Compound I designated Form IV, which is described below in Examples 16 and 19.

[0066] In some embodiments, Form IV of the maleate salt of the compound of Formula I above has at least one XRPD peak selected from about 3.9°, about 4.6°, about 7.8°, about 9.1°, and about 22.8°, expressed in terms of 2θ.

[0067] In some embodiments, Form IV of the maleate salt of the compound of Formula I above has at least two XRPD peaks selected from about 3.9°, about 4.6°, about 7.8°, about 9.1°, and about 22.8°, expressed in terms of 2θ.

[0068] In some embodiments, Form IV of the maleate salt of the compound of Formula I above has at least three XRPD peaks selected from about 3.9°, about 4.6°, about 7.8°, about 9.1°, and about 22.8°, expressed in terms of 2θ.

[0069] In some embodiments, Form IV of the maleate salt of the compound of Formula I above has at least four XRPD peaks selected from about 3.9°, about 4.6°, about 7.8°, about 9.1°, and about 22.8°, expressed in terms of 2θ.

[0070] In some embodiments, Form IV of the maleate salt of the compound of Formula I above has the following XRPD peaks, expressed in terms of 2θ: about 3.9°, about 4.6°, about 7.8°, about 9.1°, and about 22.8°.

[0071] In some embodiments, Form IV of the maleate salt of the compound of Formula I above has the following XRPD peaks, expressed in terms of 2θ: about 3.9°, about 4.6°, about 7.8°, and about 9.1°.

[0072] In some embodiments, Form IV of the maleate salt of the compound of Formula I above has an XRPD profile substantially as shown in FIG.

[0073] In some embodiments, Form IV of the maleate salt of the compound of Formula I has endothermic peaks in a DSC curve at about 152.1° C. and about 202.6° C. In some embodiments, Form IV of the maleate salt of the compound of Formula I has an endothermic peak in a DSC curve at about 152.1° C. In some embodiments, Form IV of the maleate salt of the compound of Formula I has an endothermic peak in a DSC curve at about 202.6° C.

[0074] In some embodiments, Form IV of the maleate salt of the compound of Formula I above has a DSC curve substantially as shown in FIG.

[0075] In some embodiments, Form IV of the maleate salt of the compound of Formula I above has a TGA curve substantially as shown in FIG.

[0076] The maleate salt of the compound of formula I, Form V: Provided herein is a crystalline form of Compound I designated Form V, which is described below in Examples 16 and 20.

[0077] In some embodiments, Form V of the maleate salt of the compound of Formula I above has at least one XRPD peak selected from about 4.1°, about 8.3°, about 8.8°, about 18.0°, and about 27.3°, expressed in terms of 2θ.

[0078] In some embodiments, Form V of the maleate salt of the compound of Formula I has at least two XRPD peaks selected from about 4.1°, about 8.3°, about 8.8°, about 18.0°, and about 27.3°, expressed in terms of 2θ.

[0079] In some embodiments, Form V of the maleate salt of the compound of Formula I has at least three XRPD peaks selected from about 4.1°, about 8.3°, about 8.8°, about 18.0°, and about 27.3° in terms of 2θ.

[0080] In some embodiments, Form V of the maleate salt of the compound of Formula I above has at least four XRPD peaks selected from about 4.1°, about 8.3°, about 8.8°, about 18.0°, and about 27.3° in terms of 2θ.

[0081] In some embodiments, Form V of the maleate salt of the compound of Formula I above has the following XRPD peaks, expressed in terms of 2θ: about 4.1°, about 8.3°, about 8.8°, about 18.0°, and about 27.3°.

[0082] In some embodiments, Form V of the maleate salt of the compound of Formula I above has the following XRPD peaks, expressed in terms of 2θ: about 4.1°, about 8.3°, about 8.8°, and about 27.3°.

[0083] In some embodiments, Form V of the maleate salt of the compound of formula I above has an XRPD profile substantially as shown in FIG.

[0084] In some embodiments, Form V of the maleate salt of the compound of Formula I above has an endothermic peak at about 200.1° C. in the DSC curve.

[0085] In some embodiments, Form V of the maleate salt of the compound of Formula I above has a DSC curve substantially as shown in FIG.

[0086] In some embodiments, Form V of the maleate salt of the compound of Formula I above has a TGA curve substantially as shown in FIG.

[0087] The present application provides compounds of formula II: [ka] or pharma- ceutically acceptable hydrates and solvates thereof.

[0088] Thus, in some embodiments, the present application provides: N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide phosphate, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hydrochloride, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide salicylate, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide methanesulfonate, and N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide ethanesulfonate A salt selected from or pharma-ceutically acceptable solvates and hydrates thereof. to provide.

[0089] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide phosphate salt (also referred to herein as the phosphate salt of the compound of Formula II, the phosphate salt of Compound II, Compound II phosphate salt, or any variation thereof).

[0090] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to phosphoric acid.

[0091] In some embodiments, the phosphate salt of the compound of formula II above is crystalline.

[0092] In some embodiments, the phosphate salt of the compound of formula II above is substantially isolated.

[0093] In some embodiments, the phosphate salt of the compound of formula II has at least one XRPD peak selected from about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3° in 2θ. In some embodiments, the phosphate salt of the compound of formula II has at least two XRPD peaks selected from about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3° in 2θ. In some embodiments, the phosphate salt of the compound of formula II has at least three XRPD peaks selected from about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3° in 2θ. In some embodiments, the phosphate salt of the compound of formula II has at least four XRPD peaks selected from about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3°, expressed in terms of 2θ. In some embodiments, the phosphate salt of the compound of formula II has the following XRPD peaks, expressed in terms of 2θ: about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3°.

[0094] In some embodiments, the phosphate salt of the compound of formula II above has an XRPD profile substantially as shown in FIG.

[0095] In some embodiments, the phosphate salt of the compound of formula II has a DSC curve with an endothermic peak at about 257.2° C. In some embodiments, the phosphate salt of the compound of formula II has a DSC curve substantially as shown in FIG. 5. In some embodiments, the phosphate salt of the compound of formula II has a TGA curve substantially as shown in FIG. 6.

[0096] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate (also referred to herein as the maleate salt of the compound of Formula II, the maleate salt of Compound II, Compound II maleate salt, or any variation thereof).

[0097] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to maleic acid.

[0098] In some embodiments, the maleate salt of the compound of formula II above is crystalline.

[0099] In some embodiments, the maleate salt of the compound of formula II above is substantially isolated.

[0100] In some embodiments, the maleate salt of the compound of formula II has at least one XRPD peak selected from about 4.5°, about 6.5°, about 14.1°, about 24.0°, and about 28.2° in 2θ. In some embodiments, the maleate salt of the compound of formula II has at least two XRPD peaks selected from about 4.5°, about 6.5°, about 14.1°, about 24.0°, and about 28.2° in 2θ. In some embodiments, the maleate salt of the compound of formula II has at least three XRPD peaks selected from about 4.5°, about 6.5°, about 14.1°, about 24.0°, and about 28.2° in 2θ. In some embodiments, the maleate salt of the compound of formula II has at least four XRPD peaks selected from about 4.5°, about 6.5°, about 14.1°, about 24.0°, and about 28.2°, expressed in terms of 2θ. In some embodiments, the maleate salt of the compound of formula II has the following XRPD peaks, expressed in terms of 2θ: about 4.5°, about 6.5°, about 14.1°, about 24.0°, and about 28.2°.

[0101] In some embodiments, the maleate salt of the compound of formula II above has an XRPD profile substantially as shown in FIG.

[0102] In some embodiments, the maleate salt of the compound of formula II has a DSC curve with endothermic peaks at about 194.8° C. and / or about 239.7° C. In some embodiments, the maleate salt of the compound of formula II has a DSC curve substantially as shown in FIG. 8. In some embodiments, the maleate salt of the compound of formula II has a TGA curve substantially as shown in FIG. 9.

[0103] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate (also referred to herein as the hemi-sulfate salt of the compound of Formula II, the hemi-sulfate salt of Compound II, Compound II hemi-sulfate salt, or any variation thereof).

[0104] In some embodiments, the salt is a salt having a stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to sulfuric acid of 1:0.5 (i.e., 2:1).

[0105] In some embodiments, the hemisulfate salt of the compound of formula II above is crystalline.

[0106] In some embodiments, the hemisulfate salt of the compound of formula II above is substantially isolated.

[0107] In some embodiments, the hemisulfate salt of the compound of formula II has at least one XRPD peak selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and 24.9° in 2θ. In some embodiments, the hemisulfate salt of the compound of formula II has at least two XRPD peaks selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and 24.9° in 2θ. In some embodiments, the hemisulfate salt of the compound of formula II has at least three XRPD peaks selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and 24.9° in 2θ. In some embodiments, the hemisulfate salt of the compound of formula II has at least four XRPD peaks selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and 24.9° in terms of 2θ. In some embodiments, the hemisulfate salt of the compound of formula II has the following XRPD peaks in terms of 2θ: about 5.3°, about 8.5°, about 15.3°, about 20.1°, and 24.9°.

[0108] In some embodiments, the hemisulfate salt of the compound of formula II above has an XRPD profile substantially as shown in FIG.

[0109] In some embodiments, the hemisulfate salt of the compound of formula II has a DSC curve with an endothermic peak at about 289.4° C. In some embodiments, the hemisulfate salt of the compound of formula II has a DSC curve substantially as shown in FIG. 11. In some embodiments, the hemisulfate salt of the compound of formula II has a TGA curve substantially as shown in FIG.

[0110] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hydrochloride (also referred to herein as the hydrochloride salt of the compound of Formula II, the hydrochloride salt of Compound II, Compound II hydrochloride salt, or any variation thereof).

[0111] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to hydrochloric acid.

[0112] In some embodiments, the hydrochloride salt of the compound of formula II above is crystalline.

[0113] In some embodiments, the hydrochloride salt of the compound of formula II above is substantially isolated.

[0114] In some embodiments, the hydrochloride salt of the compound of formula II has at least one XRPD peak selected from about 6.5°, about 9.7°, about 14.9°, about 21.5°, and about 23.9° in 2θ. In some embodiments, the hydrochloride salt of the compound of formula II has at least two XRPD peaks selected from about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3° in 2θ. In some embodiments, the hydrochloride salt of the compound of formula II has at least three XRPD peaks selected from about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3° in 2θ. In some embodiments, the hydrochloride salt of the compound of formula II has at least four XRPD peaks selected from about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3°, expressed in terms of 2θ. In some embodiments, the hydrochloride salt of the compound of formula II has the following XRPD peaks, expressed in terms of 2θ: about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3°.

[0115] In some embodiments, the hydrochloride salt of the compound of formula II above has an XRPD profile substantially as shown in FIG.

[0116] In some embodiments, the hydrochloride salt of the compound of formula II has a DSC curve with an endothermic peak at about 190° C. In some embodiments, the hydrochloride salt of the compound of formula II has a DSC curve substantially as shown in FIG. 14. In some embodiments, the hydrochloride salt of the compound of formula II has a TGA curve substantially as shown in FIG.

[0117] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide salicylate (also referred to herein as the salicylate salt of the compound of Formula II, the salicylate salt of Compound II, Compound II salicylate salt, or any variation thereof).

[0118] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to salicylic acid.

[0119] In some embodiments, the salicylate salt of the compound of formula II above is crystalline.

[0120] In some embodiments, the salicylate salt of the compound of formula II above is substantially isolated.

[0121] In some embodiments, the salicylate salt of the compound of formula II has at least one XRPD peak selected from about 7.3°, about 14.4°, about 15.7°, about 19.9°, and about 21.9° in 2θ. In some embodiments, the salicylate salt of the compound of formula II has at least two XRPD peaks selected from about 7.3°, about 14.4°, about 15.7°, about 19.9°, and about 21.9° in 2θ. In some embodiments, the salicylate salt of the compound of formula II has at least three XRPD peaks selected from about 7.3°, about 14.4°, about 15.7°, about 19.9°, and about 21.9° in 2θ. In some embodiments, the salicylate salt of the compound of formula II has at least four XRPD peaks selected from about 7.3°, about 14.4°, about 15.7°, about 19.9°, and about 21.9°, expressed in terms of 2θ. In some embodiments, the salicylate salt of the compound of formula II has the following XRPD peaks, expressed in terms of 2θ: about 7.3°, about 14.4°, about 15.7°, about 19.9°, and about 21.9°.

[0122] In some embodiments, the salicylate salt of the compound of formula II above has an XRPD profile substantially as shown in FIG.

[0123] In some embodiments, the salicylate salt of the compound of formula II has a DSC curve with endothermic peaks at about 181.7° C., about 224.9° C., and / or about 264.5° C. In some embodiments, the salicylate salt of the compound of formula II has a DSC curve substantially as shown in FIG. 17. In some embodiments, the salicylate salt of the compound of formula II has a TGA curve substantially as shown in FIG.

[0124] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide methanesulfonate salt (also referred to herein as the mesylate salt of the compound of Formula II, the mesylate salt of Compound II, Compound II mesylate salt, or any variation thereof).

[0125] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to methanesulfonic acid.

[0126] In some embodiments, the methanesulfonate salt of the compound of formula II above is crystalline.

[0127] In some embodiments, the methanesulfonate salt of the compound of formula II above is substantially isolated.

[0128] In some embodiments, the methanesulfonate salt of the compound of formula II has at least one XRPD peak selected from about 5.0°, about 8.2°, about 13.2°, and about 16.9° in 2θ. In some embodiments, the methanesulfonate salt of the compound of formula II has at least two XRPD peaks selected from about 5.0°, about 8.2°, about 13.2°, and about 16.9° in 2θ. In some embodiments, the methanesulfonate salt of the compound of formula II has at least three XRPD peaks selected from about 5.0°, about 8.2°, about 13.2°, and about 16.9° in 2θ. In some embodiments, the methanesulfonate salt of the compound of formula II has the following XRPD peaks selected from about 5.0°, about 8.2°, about 13.2°, and about 16.9° in 2θ:

[0129] In some embodiments, the methanesulfonate salt of the compound of formula II above has an XRPD profile substantially as shown in FIG.

[0130] In some embodiments, the methanesulfonate salt of the compound of formula II has a DSC curve with an endothermic peak at about 174.8° C. In some embodiments, the methanesulfonate salt of the compound of formula II has a DSC curve substantially as shown in FIG. 20. In some embodiments, the methanesulfonate salt of the compound of formula II has a TGA curve substantially as shown in FIG.

[0131] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide ethanesulfonate (also referred to herein as the esylate salt of the compound of Formula II, the esylate salt of Compound II, Compound II esylate salt, or any variation thereof).

[0132] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to ethanesulfonic acid.

[0133] In some embodiments, the ethanesulfonic acid salt of the compound of formula II above is crystalline.

[0134] In some embodiments, the ethanesulfonic acid salt of the compound of formula II above is substantially isolated.

[0135] In some embodiments, the ethanesulfonate salt of the compound of formula II has at least one XRPD peak selected from about 4.9°, about 7.6°, about 15.4°, about 16.8°, and about 17.5° in 2θ. In some embodiments, the ethanesulfonate salt of the compound of formula II has at least two XRPD peaks selected from about 4.9°, about 7.6°, about 15.4°, about 16.8°, and about 17.5° in 2θ. In some embodiments, the ethanesulfonate salt of the compound of formula II has at least three XRPD peaks selected from about 4.9°, about 7.6°, about 15.4°, about 16.8°, and about 17.5° in 2θ. In some embodiments, the ethanesulfonate salt of the compound of formula II has at least four XRPD peaks selected from about 4.9°, about 7.6°, about 15.4°, about 16.8°, and about 17.5° in terms of 2θ. In some embodiments, the ethanesulfonate salt of the compound of formula II has the following XRPD peaks in terms of 2θ: about 4.9°, about 7.6°, about 15.4°, about 16.8°, and about 17.5°. In some embodiments, the ethanesulfonate salt of the compound of formula II has the following XRPD peaks in terms of 2θ: about 4.9°, about 7.6°, about 15.4°, and about 17.5°.

[0136] In some embodiments, the ethanesulfonic acid salt of the compound of formula II above has an XRPD profile substantially as shown in FIG.

[0137] In some embodiments, the ethanesulfonate salt of the compound of formula II has a DSC curve with an endothermic peak at about 187.7° C. In some embodiments, the esylate salt of the compound of formula II has a DSC curve substantially as shown in FIG. 23. In some embodiments, the esylate salt of the compound of formula II has a TGA curve substantially as shown in FIG.

[0138] Manufacturing method The present application relates to formula I: [ka] A method for producing the salt of is further provided.

[0139] Thus, there is provided herein a process for preparing a salt, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate, comprising reacting a compound of formula I with maleic acid to form the salt. A process for preparing the maleate salt of compound of formula I is shown in Scheme 1 and described in Example 1.

[0140] In some embodiments, about 1 equivalent of maleic acid is used based on 1 equivalent of the compound of Formula I.

[0141] In some embodiments, reacting the compound of formula I with maleic acid is carried out in the presence of a solvent component.

[0142] In some embodiments, the solvent component comprises methanol.

[0143] In some embodiments, the solvent component comprises dichloromethane.

[0144] In some embodiments, the solvent component comprises methanol and dichloromethane.

[0145] In some embodiments, the process further comprises removing a substantial portion of the dichloromethane to precipitate the salt.

[0146] In some embodiments, the process further comprises removing a substantial portion of the dichloromethane to precipitate the salt.

[0147] In some embodiments, the process further comprises forming a solution of the compound of Formula I in a solvent component prior to said reacting.

[0148] In a further embodiment, the solution is formed by heating a slurry of the compound of Formula I in the solvent component to a temperature of about 45°C to about 55°C.

[0149] In a further embodiment, the process further comprises stirring the solution and filtering the solution to form a filtrate prior to reacting the compound of formula I with maleic acid.

[0150] In a further embodiment, the method further comprises adding activated carbon and silica gel to the solution after heating the slurry to a temperature of about 45° C. to about 55° C. to form a solution and before stirring the solution.

[0151] In some embodiments, the method for preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate comprises the steps of: adding a compound of formula I to a solvent component at room temperature to form a slurry; heating the slurry to a temperature of about 45° C. to about 55° C. to form a solution; Stirring the solution; and filtering the solution to obtain a filtrate; adding maleic acid to the filtrate; removing the solvent from the filtrate to precipitate the salt; Includes.

[0152] In some embodiments, the solvent component comprises methanol.

[0153] In some embodiments, the solvent component comprises dichloromethane.

[0154] In some embodiments, the solvent component comprises methanol and dichloromethane.

[0155] In some embodiments, the method further comprises adding activated carbon to the solution after heating the slurry to a temperature of about 45° C. to about 55° C. to form a solution and before agitating the solution.

[0156] In some embodiments, the method further comprises adding silica gel to the solution after heating the slurry to a temperature of about 45° C. to about 55° C. to form a solution and before stirring the solution.

[0157] In some embodiments, the method further comprises adding activated carbon and silica gel to the solution after heating the slurry to a temperature of about 45° C. to about 55° C. to form a solution and before stirring the solution.

[0158] Provided herein is a process for preparing Form II of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate, which comprises distilling off a saturated solution of compound I maleate in chloroform at 25±1° C. The process for preparing Form II of the maleate of compound I above is described in Example 16, Table 10.

[0159] Provided herein is a process for preparing Form III of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate, which comprises distilling off a saturated solution of compound I maleate in 1,4-dioxane at 25±1° C. The process for preparing Form III of the maleate of compound I above is described in Example 16, Table 10.

[0160] Provided herein is a process for preparing Form IV of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate, which comprises distilling off a saturated solution of compound I maleate in n-BuOH at 50±1° C. The process for preparing Form IV of the maleate of compound I above is described in Example 16, Table 10.

[0161] Provided herein is a process for preparing Form V of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate, which comprises adding a saturated solution of compound I maleate in dichloromethane to heptane and stirring. The process for preparing Form V of the maleate of compound I above is described in Example 16, Table 10.

[0162] The present application relates to a compound of formula II: [ka] A method for producing the salt of is further provided.

[0163] Thus, there is provided herein a process for the preparation of a salt which is N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate, said process comprising reacting a compound of formula II with sulfuric acid to form said salt. A process for the preparation of the hemisulfate salt of compound of formula II is described in Example 8, Table 2.

[0164] In some embodiments, about 0.6 equivalents of sulfuric acid are used based on 1 equivalent of the compound of formula II.

[0165] In some embodiments, the method further comprises: adding a compound of formula II to a solvent component to form a solution; adding sulfuric acid to the solution at room temperature; concentrating the solution to form a slurry; Stirring the slurry at a temperature of about 60° C. to about 70° C.; cooling the slurry to a temperature of about 15° C. to about 25° C. to precipitate the salt. Includes.

[0166] In some embodiments, the solvent component comprises methanol.

[0167] In some embodiments, the solvent component comprises dichloromethane.

[0168] In some embodiments, the solvent component comprises methanol and dichloromethane.

[0169] In some embodiments, the sulfuric acid is about 1 M in water.

[0170] In some embodiments, the method further comprises preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate. A method for preparing the sulfate salt of the compound of Formula II is shown in Scheme 2 and described in Example 2.

[0171] In some embodiments, the method for preparing the salt N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate comprises reacting a compound of formula II with about 1 equivalent of sulfuric acid based on 1 equivalent of the compound of formula II.

[0172] In some embodiments, the method for preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate comprises: adding a compound of formula II to a first solvent component at room temperature to form a solution; Heating the solution to a temperature of 50°C to 60°C; adding sulfuric acid to the solution; removing the solvent to precipitate the sulfate salt; Includes.

[0173] In some embodiments, the first solvent component comprises methanol.

[0174] In some embodiments, the sulfuric acid is added as an aqueous solution.

[0175] In some embodiments, the method for preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate comprises the steps of: adding the N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate to a second solvent component to form a slurry; heating the slurry to a temperature of about 30° C. to about 40° C.; agitating the slurry; collecting the hemisulfate produced; Includes.

[0176] In some embodiments, the second solvent component comprises water.

[0177] Provided herein is a method for preparing the amorphous form of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate. The method for preparing the amorphous form of the hemisulfate salt of the compound of Formula II is shown in Scheme 2 and described in Example 2.

[0178] In some embodiments, the method for preparing an amorphous form of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate comprises the steps of: adding said N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate to a third solvent component at room temperature to form a solution; filtering the solution; concentrating the filtrate; drying the resulting solid to produce the amorphous hemisulfate salt; Includes.

[0179] In some embodiments, the third solvent component comprises acetone and methanol.

[0180] Provided herein is a method for preparing a salt which is N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide phosphate, comprising reacting a compound of formula II with phosphoric acid to form the salt. A method for preparing a phosphate salt of a compound of formula II is described in Example 8, Table 2. In some embodiments, about 1.2 equivalents of phosphoric acid are used based on 1 equivalent of a compound of formula II.

[0181] Provided herein is a method for preparing a salt, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate, comprising reacting a compound of formula II with maleic acid to form the salt. A method for preparing the maleate salt of a compound of formula II is described in Example 8, Table 2. In some embodiments, about 1.5 equivalents of maleic acid are used based on 1 equivalent of a compound of formula II.

[0182] Provided herein is a method for preparing a salt, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hydrochloride, comprising reacting a compound of formula II with hydrochloric acid to form the salt. A method for preparing the hydrochloride salt of a compound of formula II is described in Example 8, Table 2. In some embodiments, about 1.2 equivalents of hydrochloric acid are used based on 1 equivalent of a compound of formula II.

[0183] Provided herein is a method for preparing a salt, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide salicylate, comprising reacting a compound of formula II with salicylic acid to form the salt. A method for preparing the salicylate salt of a compound of formula II is described in Example 8, Table 2. In some embodiments, about 1.2 equivalents of salicylic acid are used based on 1 equivalent of a compound of formula II.

[0184] Provided herein is a method for preparing a salt, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide methanesulfonate, comprising reacting a compound of formula II with methanesulfonic acid to form the salt. A method for preparing the methanesulfonate salt of a compound of formula II is described in Example 8, Table 2. In some embodiments, about 1 equivalent of methanesulfonic acid is used based on 1 equivalent of a compound of formula II.

[0185] Provided herein is a method for preparing a salt, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide ethanesulfonate, comprising reacting a compound of formula II with ethanesulfonic acid to form the salt. A method for preparing the ethanesulfonate salt of a compound of formula II is described in Example 8, Table 2. In some embodiments, about one equivalent of methanesulfonic acid is used based on one equivalent of a compound of formula II.

[0186] Certain features of the disclosure that are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment (even though such embodiments are intended to be combined in the same manner as if described in a multiple dependent manner). Conversely, various features of the disclosure that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any and all suitable subcombinations.

[0187] The salts and compounds of the present disclosure may also include all isotopes of atoms present in the intermediates or final salts or compounds. Isotopes are atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen are tritium and deuterium.

[0188] In some embodiments, the compounds or salts may be present in combination with other substances such as water and solvents (eg, hydrates and solvates) or may be isolated.

[0189] In some embodiments, a compound described herein, or a salt thereof (eg, a maleate salt of a compound of formula I or a hemisulfate salt of a compound of formula II) is substantially isolated.

[0190] The phrase "pharmacologically acceptable" is used herein to refer to compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0191] As can be seen from the above, the compounds provided herein (including their salts) can be prepared using known organic synthesis techniques and can be synthesized according to any of a number of possible synthetic routes. The preparation methods described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, or spectrophotometry (e.g., UV-visible), or by chromatography, such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC), or other related techniques.

[0192] As used herein, the term "reacting" is used as understood in the art and generally refers to contacting chemical reactants with one another in a manner that allows the chemical reactants to interact at a molecular level to achieve a chemical or physical transformation. In some embodiments, the "reacting" involves two reactants, with one or more equivalents of the second reactant relative to the first reactant being used. The reaction steps of the processes described herein can be carried out for a suitable time and under suitable conditions to produce the specified product.

[0193] The reactions of the preparation methods described herein may be carried out in a suitable solvent, which can be readily selected by one skilled in the art of organic synthesis. A suitable solvent may be substantially non-reactive with the starting materials (reactants), intermediates, or products at the temperature at which the reaction is carried out, which may range, for example, from the freezing temperature of the solvent to the boiling temperature of the solvent. A given reaction may be carried out in one solvent or a mixture of two or more solvents. Depending on the particular reaction step, a suitable solvent (or mixture of solvents) for that particular reaction step can be selected.

[0194] Suitable solvents include halogenated solvents such as carbon tetrachloride, bromodichloromethane, dibromochloromethane, bromoform, chloroform, bromochloromethane, dibromomethane, butyl chloride, dichloromethane, tetrachloroethylene, trichloroethylene, 1,1,1-trichloroethane, 1,1,2-trichloroethane, 1,1-dichloroethane, 2-chloropropane, 1,2-dichloroethane, 1,2-dibromoethane, hexafluorobenzene, 1,2,4-trichlorobenzene, 1,2-dichlorobenzene, chlorobenzene, fluorobenzene, mixtures thereof, and the like.

[0195] Suitable ether solvents include dimethoxymethane, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, triethylene glycol dimethyl ether, anisole, t-butyl methyl ether, mixtures thereof, and the like.

[0196] Suitable protic solvents may include, by way of example and without limitation, water, methanol, ethanol, 2-nitroethanol, 2-fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 1-propanol, 2-propanol, 2-methoxyethanol, 1-butanol, 2-butanol, i-butyl alcohol, t-butyl alcohol, 2-ethoxyethanol, diethylene glycol, 1-, 2-, or 3-pentanol, neopentyl alcohol, t-pentyl alcohol, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol, or glycerin.

[0197] Suitable aprotic solvents can include, by way of example and without limitation, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), 1,3-dimethyl-2-imidazolidinone (DMI), N-methylpyrrolidinone (NMP), formamide, N-methylacetamide, N-methylformamide, acetonitrile, dimethylsulfoxide, propionitrile, ethyl formate, methyl acetate, hexachloroacetone, acetone, ethyl methyl ketone, ethyl acetate, sulfolane, N,N-dimethylpropionamide, tetramethylurea, nitromethane, nitrobenzene, or hexamethylphosphoramide.

[0198] Suitable hydrocarbon solvents include benzene, cyclohexane, pentane, hexane, toluene, cycloheptane, methylcyclohexane, heptane, ethylbenzene, m-, o-, or p-xylene, octane, indane, nonane, or naphthalene.

[0199] The reactions of the process described herein can be carried out at any suitable temperature, which can be readily determined by one of ordinary skill in the art. The reaction temperature will depend, for example, on the melting and boiling points of the reactants and solvent (if present), the thermodynamics of the reaction (e.g., highly exothermic reactions may need to be carried out at lower temperatures), and the kinetics of the reaction (e.g., high activation energy barriers may require higher temperatures).

[0200] As used herein, the expressions "ambient temperature" and "room temperature" or "rt" are art-recognized and generally refer to a temperature, such as a reaction temperature, which is approximately the temperature of the room in which a reaction is carried out, e.g., a temperature of about 20° C. to about 30° C.

[0201] The reactions of the preparation methods described herein can be carried out in air or under an inert atmosphere. In general, reactions involving reactants or products that are substantially reactive with air can be carried out using techniques for air-sensitive synthesis well known to those skilled in the art.

[0202] How to use Salts of the present disclosure (e.g., salts of compounds of formula I and II) can modulate or inhibit the activity of a TAM kinase. For example, compounds of the present disclosure can be used to inhibit the activity of a TAM kinase in a cell, or an individual or patient in need of inhibition of the kinase, by administering an inhibitory amount of a compound of the present disclosure to the cell, individual, or patient.

[0203] In some embodiments, the salts of the present disclosure are selective for the TAM kinase over one or more other kinases. In some embodiments, the compounds of the present disclosure are selective for the TAM kinase over other kinases. In some embodiments, the selectivity is 2-fold or more, 3-fold or more, 5-fold or more, 10-fold or more, 25-fold or more, 50-fold or more, or 100-fold or more.

[0204] The salts of the present disclosure can inhibit one or more of AXL, MER, and TYRO3. In some embodiments, the salts are selective for one TAM kinase over another. By "selective" it is meant that the compound binds to or inhibits a TAM kinase with a higher affinity or a higher potency, respectively, compared to a reference enzyme, such as another TAM kinase. For example, the salts may be selective for AXL over MER and TYRO3, selective for MER over AXL and TYRO3, or selective for AXL and MER over TYRO3. In some embodiments, the salts inhibit all of the TAM family members (e.g., AXL, MER, and TYRO3). In some embodiments, the salts may be selective for AXL and MER over TYRO3 and other kinases. In some embodiments, provided herein is a method of inhibiting AXL and MER kinases, comprising contacting the AXL and MER kinases with a salt provided herein, or a pharma- ceutically acceptable salt thereof.

[0205] The compounds of the present disclosure, as TAM kinase inhibitors, are useful for treating various diseases associated with the abnormal expression or activity of the TAM kinase. Salts of compounds (of formulas I and II) that inhibit TAM kinases are useful for providing a means of preventing proliferation or inducing apoptosis in tumors, particularly by inhibiting angiogenesis. It is therefore expected that the salts will prove useful for treating or preventing proliferative disorders such as cancer. In particular, tumors with mutants that activate receptor tyrosine kinases or upregulation of receptor tyrosine kinases may be particularly sensitive to the inhibitors.

[0206] In certain embodiments, the disclosure provides a method of treating a disease or disorder mediated by a TAM kinase in a patient in need thereof, comprising administering to the patient a salt provided herein (e.g., a salt of a compound of Formula I or II), or a pharma- ceutically acceptable composition thereof.

[0207] For example, the salts of the present disclosure are useful in the treatment of cancer. Examples of cancer include bladder cancer, breast cancer, cervical cancer, colorectal cancer, cancer of the small intestine, colon cancer, rectal cancer, cancer of the anus, endometrial cancer, gastric cancer, head and neck cancer (e.g., cancer of the larynx, hypopharynx, nasopharynx, oropharynx, lip, and oral cavity), kidney cancer, liver cancer (e.g., hepatocellular carcinoma, cholangiocarcinoma), lung cancer (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung cancer, small cell and small cell carcinoma, bronchial carcinoma, bronchial adenoma, pleuropulmonary blastoma), ovarian cancer, prostate cancer, testicular cancer, uterine cancer, esophageal cancer, gallbladder cancer, pancreatic cancer (e.g., exocrine pancreatic cancer), stomach cancer, thyroid cancer, parathyroid cancer, skin cancer (e.g., squamous cell carcinoma, Kaposi's sarcoma, Merkel cell skin cancer), and brain cancer (e.g., astrocytoma, medulloblastoma, ependymoma, neuroectodermal tumor, pineal tumor).

[0208] Other cancers treatable by the compounds of the present disclosure include bone cancer, intraocular cancer, gynecological cancer, cancer of the endocrine system, cancer of the adrenal gland, soft tissue sarcoma, cancer of the urethra, cancer of the penis, pituitary cancer, triple negative breast cancer (TNBC), and environmentally induced cancers, including asbestos induced cancer.

[0209] Further examples of cancer include hematopoietic malignancies such as leukemia or lymphoma, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, cutaneous T-cell lymphoma, acute myeloid leukemia, Hodgkin's or non-Hodgkin's lymphoma, myeloproliferative neoplasms (e.g., polycythemia vera, essential thrombocythemia, and primary myelofibrosis), Waldenstrom's macroglobulinemia, hairy cell lymphoma, chronic myeloid lymphoma, acute lymphoblastic lymphoma, AIDS-related lymphoma, and Burkitt's lymphoma.

[0210] Other cancers treatable by the compounds of the present disclosure include eye tumors, glioblastoma, melanoma, rhabdomyosarcoma, lymphosarcoma, and osteosarcoma.

[0211] The salts of the present disclosure may also be useful in inhibiting tumor metastasis.

[0212] In some embodiments, diseases and indications treatable using compounds of the present disclosure include, but are not limited to, hematological cancers, sarcomas, lung cancer, gastrointestinal cancers, genitourinary cancers, liver cancer, bone cancer, nervous system cancers, gynecological cancers, and skin cancers.

[0213] Exemplary hematological cancers include acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), non-Hodgkin's lymphoma (NHL) (including relapsed or refractory NHL), follicular lymphoma (FL), Hodgkin's lymphoma (HL), and leukemia. lymphomas and leukemias, such as lymphoma, lymphoblastic lymphoma, myeloproliferative disorders (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET)), myelodysplastic syndromes (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), multiple myeloma, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, Waldenstrom's macroglobulinemia, hairy cell lymphoma, chronic myelogenous lymphoma, and Burkitt's lymphoma.

[0214] Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdomyosarcoma, fibroma, lipoma, mesodermoma, and teratoma.

[0215] Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchial carcinoma (squamous cell, small undifferentiated cell, large undifferentiated cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondrohamartoma, and mesothelioma.

[0216] Exemplary gastrointestinal cancers include cancer of the esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), cancer of the stomach (carcinoma, lymphoma, leiomyosarcoma), cancer of the pancreas (tubular adenocarcinoma, islet cell adenoma, glucagonoma, gastrinoma, carcinoid tumor, VIPoma), cancer of the small intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), cancer of the large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colorectal cancer, and bile duct cancer.

[0217] Exemplary genitourinary tract cancers include cancer of the kidney (adenocarcinoma, Wilms' tumor [nephroblastoma], renal cell carcinoma), cancer of the bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma, urothelial carcinoma), cancer of the prostate (adenocarcinoma, sarcoma), and cancer of the testes (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatous tumor, lipoma).

[0218] Exemplary liver cancers include hepatocellular carcinoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.

[0219] Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor, chordoma, osteochondral chondrochondroma (osteochondral exostosis), chondroblastoma, chondromyxoid fibroma, osteoid osteoma, giant cell tumor.

[0220] Exemplary nervous system cancers include cancers of the skull (osteoma, hemangioma, granuloma, xanthomas, osteitis deformans), meninges (meningioma, meningeal sarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma, glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), as well as neuroblastoma, Lhermitte-Duclos disease, central nervous system (CNS) neoplasms, primary CNS lymphoma, and spinal axis tumors.

[0221] Exemplary gynecological cancers include cancer of the uterus (endometrial carcinoma), cancer of the cervix (cervical carcinoma, preneoplastic cervical dysplasia), cancer of the ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa follicular cell tumor, Sertoli-Leydic cell tumor, dysgerminoma, malignant teratoma), cancer of the vulva (squamous cell carcinoma, carcinoma in situ, adenocarcinoma, fibrosarcoma, melanoma), cancer of the vagina (clear cell carcinoma, squamous cell carcinoma, botryoid rhabdomyosarcoma (embryonal rhabdomyosarcoma)), and cancer of the fallopian tubes (carcinoma).

[0222] Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell skin cancer, lenticular dysplasia nevus, lipoma, hemangioma, dermatofibroma, and keloids.

[0223] Exemplary head and neck cancers include glioblastoma, melanoma, rhabdomyosarcoma, lymphosarcoma, osteosarcoma, squamous cell carcinoma, adenocarcinoma, oral cavity cancer, laryngeal cancer, nasopharyngeal cancer, nasal and paranasal cancer, thyroid cancer, and parathyroid cancer.

[0224] In some embodiments, the disclosure provides a method of treating hepatocellular carcinoma in a patient in need thereof, comprising administering to the patient a salt of a compound of formula I or a salt of a compound of formula II, or a composition comprising a salt of a compound of formula I or a salt of a compound of formula II.

[0225] In some embodiments, the disclosure provides a method of treating rhabdomyosarcoma, esophageal cancer, breast cancer, or head and neck cancer in a patient in need thereof, comprising administering to the patient a salt of a compound of formula I or a salt of a compound of formula II, or a composition comprising a salt of a compound of formula I or a salt of a compound of formula II.

[0226] In some embodiments, the present disclosure provides a method of treating a cancer selected from hepatocellular carcinoma, breast cancer, bladder cancer, colorectal cancer, melanoma, mesothelioma, lung cancer, prostate cancer, pancreatic cancer, testicular cancer, thyroid cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, uterine cancer, and rhabdomyosarcoma.

[0227] Targeting TAM receptor tyrosine kinase can provide a therapeutic approach for treating viral diseases (T Shibata, et al. The Journal of Immunology, 2014, 192, 3569-3581). The present disclosure provides a method for treating infectious diseases, such as viral infections. The method comprises administering to a patient in need thereof a therapeutically effective amount of a salt of a compound of formula I or a salt of a compound of formula II, or a composition comprising a salt of a compound of formula I or a salt of a compound of formula II.

[0228] Examples of viruses causing infectious diseases treatable by the methods of the present disclosure include, but are not limited to, human immunodeficiency virus; human papillomavirus; influenza virus; hepatitis A, B, C, or D virus; adenovirus; poxvirus; herpes simplex virus; human cytomegalovirus; severe acute respiratory syndrome virus; Ebola virus; Marburg virus; and measles virus. In some embodiments, examples of viruses causing infectious diseases treatable by the methods of the present disclosure include, but are not limited to, hepatitis (A, B, or C) viruses, herpes viruses (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein-Barr virus), adenovirus, influenza virus, flavivirus (e.g., West Nile virus, dengue virus, tick-borne encephalitis virus, yellow fever virus, Zika virus), echovirus, rhinovirus, coxsackievirus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papilloma virus, molluscum contagiosum virus, poliovirus, rabies virus, JC virus, and arboviral encephalitis virus.

[0229] In some embodiments, the present disclosure provides methods for treating thrombus formation (JMEM Cosemans et al. J. of Thrombosis and Haemostasis 2010, 8, 1797-1808 and A. Angelillo-Scherrer et al. J. Clin. Invest. 2008, 118, 583-596).

[0230] Combination therapy One or more additional medicaments or therapeutic methods, such as antiviral agents, chemotherapeutic or other anti-cancer agents, immunoenhancing agents, immunosuppressants, radiation, antitumor and antiviral vaccines, cytokine therapies (e.g., IL-2, GM-CSF, etc.), and / or tyrosine kinase inhibitors, may be used in combination with a compound of Formula I or a compound described herein to treat a TAM-associated disease, disorder, or condition. The medicaments may be combined with the salts (e.g., salts of the compounds of Formula I and II) in a single dosage form, or the medicaments may be administered simultaneously or sequentially as separate dosage forms.

[0231] Suitable antiviral agents contemplated for use in combination with the salts of the present disclosure can include nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, and other antiviral agents.

[0232] Examples of suitable NRTIs include zidovudine (AZT), didanosine (ddl), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), abacavir (1592U89), adefovir dipivoxil [bis(POM)-PMEA], lobucavir (BMS-180194), BCH-10652, emitricitabine [(-)-FTC], β-L-FD4 (also known as β-L-D4C, which has the name β-L-2',3'-dicreoxy-5-fluorocytidine), DAPD ((-)-β-D-2,6-diaminopurine dioxolane), and rhodenosine (FddA). Commonly suitable NNRTIs include nevirapine (BI-RG-587), delaviradine (BHAP, U-90152), efavirenz (DMP-266), PNU-142721, AG-1549, MKC-442 (1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimidinedione), and (+)-calanolide A (NSC-675451) and B. Commonly suitable protease inhibitors include saquinavir (Ro 31-8959), ritonavir (ABT-538), indinavir (MK-639), nerufunavir (AG-1343), amprenavir (141W94), lascinavir (BMS-234475), DMP-450, BMS-2322623, ABT-378, AG-1 549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside, and Yissum Project No. 11607.

[0233] Suitable drugs for use in combination with the salts of the present application in the treatment of cancer include chemotherapy, targeted cancer therapy, immunotherapy, or radiation therapy. The salts of the present disclosure may be effective in combination with antihormonal agents for the treatment of breast cancer and other tumors. Suitable examples include antiestrogens, including but not limited to tamoxifen and toremifene; aromatase inhibitors, including but not limited to letrozole, anastrozole, and exemestane; corticosteroids (e.g., prednisone); progestins (e.g., megastrol acetate); and estrogen receptor antagonists (e.g., fulvestrant). Suitable antihormonal agents used in the treatment of prostate cancer and other cancers may also be used in combination with the compounds of the present disclosure. These antihormonal agents include antiandrogens, including, but not limited to, flutamide, bicalutamide, and nilutamide; luteinizing hormone-releasing hormone (LHRH) analogs, including leuprolide, oserelin, triptorelin, and histrelin; LHRH antagonists (e.g., degarelix); androgen receptor blockers (e.g., enzalutamide); and agents that inhibit androgen production (e.g., abiraterone).

[0234] The salts of the present disclosure may be combined with other agents against membrane receptor kinases, or may be combined sequentially with other agents, especially for patients who have developed resistance to primary or acquired targeted therapy. These therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR, c-Met, Ret, IGFR1, PDGFR, FGFR1, FGFR2, FGFR3, FGFR4, TrkA, TrkB, TrkC, ROS, c-Kit, or Flt-3, and against cancer-related fusion protein kinases such as Bcr-Abl and EML4-Alk. Inhibitors against EGFR include gefitinib and erlotinib, and inhibitors against EGFR / Her2 include, but are not limited to, dacomitinib, afatinib, lapitinib, and neratinib. Antibodies against EGFR include, but are not limited to, cetuximab, panitumumab, and necitumumab. Inhibitors of c-Met may be used in combination with TAM inhibitors. Inhibitors of c-Met include onartuzumab, tivantinib, and INC-280. Drugs against FGFR include, but are not limited to, AZD4547, BAY1187982, ARQ087, BGJ398, BIBF1120, TKI258, lucitanib, dovitinib, TAS-120, JNJ-42756493, and Debio 1347. Drugs against Trk include, but are not limited to, LOXO-101 and RXDX-101. Drugs against Abl (or Bcr-Abl) include imatinib, dasatinib, nilotinib, and ponatinib, and drugs against Alk (or EML4-ALK) include crizotinib.

[0235] Angiogenesis inhibitors may be effective in some tumors in combination with TAM inhibitors. These angiogenesis inhibitors include antibodies against VEGF or VEGFR or kinase inhibitors of VEGFR. Antibodies against VEGF or other therapeutic proteins include bevacizumab and aflibercept. Inhibitors of VEGFR kinase and other antiangiogenesis inhibitors include, but are not limited to, sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib, and vandetanib.

[0236] In cancer, activation of intracellular signaling pathways is frequent, and drugs that target components of these pathways have been used in combination with drugs that target receptors to improve efficacy and reduce resistance. Examples of drugs that can be used in combination with the compounds of the present disclosure include inhibitors of PI3K-AKT-mTOR pathway, inhibitors of Raf-MAPK pathway, inhibitors of JAK-STAT pathway, inhibitors of Pim kinase, and inhibitors of protein chaperones and cell cycle progression.

[0237] Drugs against PI3 kinase include, but are not limited to, piralalisib, idelalisib, buparlisib, and IPI-549. In some embodiments, the PI3K inhibitor is selective for PI3Kα, PI3Kβ, PI3Kγ, or PI3Kδ. Inhibitors of mTOR, such as rapamycin, sirolimus, temsirolimus, and everolimus, may be used in combination with TAM kinase inhibitors. Other suitable examples include, but are not limited to, vemurafenib and dabrafenib (Raf inhibitors), and trametinib, selumetinib, and GDC-0973 (MEK inhibitors). One or more JAK inhibitors (e.g., ruxolitinib, baricitinib, tofacitinib), Hsp90 inhibitors (e.g., tamspimycin), cyclin-dependent kinase inhibitors (e.g., palbociclib), PARP inhibitors (e.g., olaparib), and proteasome inhibitors (e.g., bortezomib, carfilzomib) may also be used in combination with the compounds of the present disclosure. In some embodiments, the JAK inhibitor is selective for JAK1 over JAK2 and JAK3. Agents against Pim kinases include, but are not limited to, LGH447, INCB053914, and SGI-1776.

[0238] Other agents suitable for combination with the salts of the present disclosure include combinations of chemotherapeutic agents such as platinum-based doublets (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane®) used in lung cancer and other solid tumors.

[0239] Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents (including, but not limited to, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas, and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (Cytoxan™), ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.

[0240] Other agents suitable for use in combination with the salts of the present disclosure include dacarbazine (DTIC), optionally in combination with other chemotherapeutic agents such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen" consisting of DTIC, BCNU, cisplatin, and tamoxifen; a combination of cisplatin, vinblastine, and DTIC; or temozolomide. The compounds provided herein may also be used in combination with immunotherapeutic agents, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) inhibitors.

[0241] Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites (including, but not limited to, folate antagonists, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors), such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatin, and gemcitabine.

[0242] Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (TAXOL™), mithramycin, deoxycoformycin, mitomycin C, L-asparaginase, interferons (especially IFN-a), etoposide, and teniposide, as well as derivatives thereof (e.g., vinca alkaloids, antitumor antibiotics, enzymes, lymphokines, and epipodophyllotoxins).

[0243] Other cytotoxic agents include navelbene, CPT-11, anastrazole, letrazole, capecitabine, reloxafine, cyclophosphamide, ifosamide, and droloxafine.

[0244] Also suitable are cytotoxic agents such as epidophyllotoxins; anti-tumor enzymes; topoisomerase inhibitors; procarbazine; mitoxantrone; platinum coordination complexes such as cisplatin and carboplatin; biological response modifiers; proliferation inhibitors; anti-hormonal therapeutics; leucovorin; tegafur; and hematopoietic growth factors.

[0245] Other anti-cancer drug(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies against costimulatory molecules such as CTLA-4, 4-1BB, and PD-1, or antibodies against cytokines (IL-10, TGF-β, etc.).

[0246] Other anti-cancer agents include CSF1R inhibitors (PLX3397, LY3022855, etc.) and CSF1R antibodies (IMC-CS4, RG7155, etc.).

[0247] Other anti-cancer agents include BET inhibitors (INCB054329, OTX015, CPI-0610, etc.), LSD1 inhibitors (GSK2979552, INCB059872, etc.), HDAC inhibitors (panobinostat, vorinostat, etc.), DNA methyltransferase inhibitors (azacytidine and decitabine), and other epigenetic modulators.

[0248] Other anti-cancer agents include the Bcl2 inhibitor ABT-199, and other inhibitors of Bcl-2 family proteins.

[0249] Other anti-cancer drugs include TGFβ receptor kinase inhibitors, such as LY2157299.

[0250] Other anti-cancer drugs include BTK inhibitors such as ibrutinib.

[0251] Other anti-cancer agents include beta-catenin pathway inhibitors, notch pathway inhibitors, and hedgehog pathway inhibitors.

[0252] Other anti-cancer agents include inhibitors of kinase-associated cell proliferation disorders, including but not limited to Aurora A, CDK1, CDK2, CDK3, CDK5, CDK7, CDK8, CDK9, ephrin receptor kinase, CHK1, CHK2, SRC, Yes, Fyn, Lck, Fer, Fes, Syk, Itk, Bmx, GSK3, JNK, PAK1, PAK2, PAK3, PAK4, PDK1, PKA, PKC, Rsk, and SGK.

[0253] Other anti-cancer agents also include those that block immune cell migration, such as antagonists to chemokine receptors, including CCR2 and CCR4.

[0254] Other anti-cancer drugs also include anti-cancer drugs that enhance the immune system, such as adjuvants or adoptive T cell transfer.

[0255] Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines, and recombinant viruses.

[0256] One or more additional immune checkpoint inhibitors may be used in combination with the salts described herein to treat TAM-associated diseases, disorders, or conditions. Exemplary immune checkpoint inhibitors include inhibitors of immune checkpoint molecules such as CD20, CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3Kδ, PI3Kγ, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, PD-1, PD-L1, and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR, and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, CD96, TIGIT, and VISTA. In some embodiments, the salts provided herein may be used in combination with one or more agents selected from a KIR inhibitor, a TIGIT inhibitor, a LAIR1 inhibitor, a CD160 inhibitor, a 2B4 inhibitor, and a TGFRβ inhibitor.

[0257] In some embodiments, the inhibitor of the immune checkpoint molecule is an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.

[0258] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-1, such as an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab, or PDR001. In some embodiments, the anti-PD1 antibody is pembrolizumab.

[0259] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-L1, such as an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A (atezolizumab) or MEDI4736 (durvalumab).

[0260] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CTLA-4, such as an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab or tremelimumab.

[0261] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of LAG3, such as an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525.

[0262] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of GITR, such as an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518, MK-4166, INCAGN01876, or MK-1248.

[0263] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of OX40, such as an anti-OX40 antibody or an OX40L fusion protein.In some embodiments, the anti-OX40 antibody is MEDI0562, INCAGN01949, GSK2831781, GSK-3174998, MOXR-0916, PF-04518600, or LAG525.In some embodiments, the OX40L fusion protein is MEDI6383.

[0264] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CD20, such as an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is obinutuzumab or rituximab.

[0265] The salts of the present disclosure may be used in combination with bispecific antibodies, in some embodiments, one of the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, OX40, TIM3, LAG3, CD137, ICOS, CD3, or a TGFβ receptor.

[0266] The salts of the present disclosure may be used in combination with one or more drugs to treat diseases such as cancer. In some embodiments, the drug is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of alkylating agents include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).

[0267] The salts of the present disclosure may be combined with other immunogenic agents, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines. Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gp100, MAGE antigens, Trp-2, MARTI, and / or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.

[0268] The salts of the present disclosure may be combined with vaccination protocols for the treatment of cancer. In some embodiments, the tumor cells are transduced to express GM-CSF. In some embodiments, the tumor vaccine includes proteins from viruses implicated in human cancers, such as human papillomavirus (HPV), hepatitis viruses (HBV and HCV), and Kaposi's herpes sarcoma virus (KHSV). In some embodiments, the salts of the present disclosure may be combined with tumor-specific antigens, such as heat shock proteins isolated from the tumor tissue itself. In some embodiments, the salts of the present disclosure may be combined with dendritic cell immunization to activate a strong anti-tumor response.

[0269] The salts of the present disclosure may be combined with bispecific macrocyclic peptides that target Fcα or Fcγ receptor expressing effector cells to tumor cells, and the salts of the present disclosure may be combined with macrocyclic peptides that activate host immune responsiveness.

[0270] The salts of the present disclosure may also be used in combination with an arginase inhibitor, such as CB-1158.

[0271] The salt of the present disclosure may be used in combination with one or more metabolic enzyme inhibitors.In some embodiments, the metabolic enzyme inhibitor is an inhibitor or IDO1, TDO, or arginase.Examples of IDO1 inhibitors include epacadostat and NGL919.

[0272] Salts of the present disclosure may also be used in combination with bone marrow transplantation to treat a variety of tumors of hematopoietic origin.

[0273] The salts of the present disclosure may be used as anticoagulants alone or in combination with other anticoagulants, including, but not limited to, apixaban, dabigatran, edoxaban, fondaparinex, heparin, rivaroxaban, and warfarin.

[0274] Methods for safely and effectively administering most of these chemotherapeutic agents are known to those of skill in the art, and the administration of these chemotherapeutic agents is described in the standard literature. For example, the administration of many of the above chemotherapeutic agents is described in the "Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ), the disclosures of which are incorporated herein by reference as if set forth in their entirety.

[0275] Pharmaceutical Preparations and Dosage Forms When used as a pharmaceutical, the salts provided herein may be administered in the form of a pharmaceutical composition, which refers to a combination of the compounds provided herein, or a pharma- ceutically acceptable salt thereof, and at least one pharma- ceutically acceptable carrier. These compositions can be prepared by methods well known in the pharmaceutical arts and can be administered by various routes, depending on whether local or systemic treatment is desired and the area to be treated. Administration can be topical (including intraocular and intranasal, vaginal, and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powder or aerosol, including by nebulizer; intratracheal, intranasal, epithelial, and transdermal), ophthalmic, oral, or parenteral. Methods of intraocular delivery can include topical administration (ocular drops), subconjunctival, periocular, or intravitreal injection, or introduction by balloon catheter or ophthalmic insert surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; or intracranial administration, e.g., intrathecal or intraventricular. Parenteral administration may be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Conventional pharmaceutical carriers; aqueous, powder, or oily bases; thickeners, and the like, may be necessary or desirable.

[0276] The present application also includes pharmaceutical compositions containing one or more salts (e.g., salts of compounds of formula I and II) provided herein as active ingredients in combination with one or more pharma- ceutically acceptable carriers. In preparing compositions of the present disclosure, the active ingredients are generally mixed with, diluted by, or enclosed within such carriers, for example, in the form of capsules, sachets, paper, or other containers. When the excipients serve as diluents, they can be solid, semi-solid, or liquid materials that act as vehicles, carriers, or media for the active ingredients. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solids or in liquid media), ointments containing up to 10% by weight of the active compounds, soft and hard gelatin capsules, suppositories, sterile injection solutions, and sterile packaged powders.

[0277] In the manufacture of a formulation, the active compound (or salt form of the present disclosure) may be milled to a suitable particle size before mixing with other ingredients. If the active compound is substantially insoluble, it may be milled to a particle size of less than 200 mesh. If the active compound is substantially water-soluble, the particle size may be adjusted by milling to a substantially uniform distribution in the formulation, for example, about 40 mesh.

[0278] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose.The formulation may further comprise lubricants such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preservatives such as methyl and propyl hydroxybenzoates; sweeteners; and flavoring agents.The composition of the present disclosure may be formulated to release the active ingredient quickly, sustained or delayed after administration to a patient by using procedures known in the art.

[0279] The compositions may be formulated in unit dosage forms, each dosage containing from about 5 to about 100 mg, more usually from about 10 to about 30 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce a desired therapeutic effect, together with an appropriate pharmaceutical excipient.

[0280] The active compounds can be effective over a wide dosage range and are generally administered in a pharma- ceutically effective amount. However, it will be understood that the amount of the compound actually administered will usually be determined by a physician depending on the relevant circumstances, including the disease being treated, the selected route of administration, the actual compound administered, the age, weight, and response to treatment of the individual patient, the severity of the patient's symptoms, and the like.

[0281] For the preparation of solid compositions such as tablets, the primary active ingredient is mixed with pharmaceutical excipients to form a solid preformulation composition containing a homogenous mixture of the compounds of the present disclosure. When these preformulation compositions are referred to as homogenous, the active ingredient is generally evenly dispersed throughout the composition so that the composition can be easily subdivided into equally effective unit dosage forms such as tablets, pills, and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above, containing, for example, 0.1 to about 500 mg of the active ingredient of the present disclosure.

[0282] The tablets or pills of the present disclosure may be coated or otherwise compounded to provide a dosage form that provides the advantage of prolonged action.For example, the tablet or pill may comprise an inner dosage component and an outer dosage component, the latter being in the form of an envelope over the former.The two components may be separated by an enteric layer that serves to resist disintegration in the stomach and allow the inner component to pass intact into the duodenum or to be delayed in release.Various materials may be used for such enteric layers or coatings, including many polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.

[0283] Liquid forms for administration orally or by injection which may contain the salts and compositions of the disclosure include aqueous solutions, suitably flavored syrups, aqueous or oily suspensions, and edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as flavored emulsions including elixirs and similar pharmaceutical vehicles.

[0284] The compositions for inhalation or insufflation include solutions and suspensions in pharma- ceutically acceptable aqueous or organic solvents, or mixtures thereof, as well as powders. The liquid or solid compositions may contain suitable pharma- ceutically acceptable excipients as described above. In some embodiments, the compositions are administered by oral or nasal respiratory route for local or systemic effect. The solution compositions may be nebulized by using an inert gas. Nebulized solutions may be inhaled directly from the nebulizing device, or the nebulizing device may be connected to a face mask tent, or intermittent positive pressure breathing machine. The solution, suspension, or powder compositions may be administered orally or nasally from a device that delivers the formulation in a suitable manner.

[0285] The amount of salt (e.g., salt of a compound of Formula I and II) or composition administered to a patient will vary depending on what is being administered, the purpose of administration, such as prophylaxis or treatment, the condition of the patient, the method of administration, etc. In therapeutic applications, a patient already suffering from a disease may be administered the composition in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. The effective dose will depend on the condition of the disease being treated, as well as the judgment of the attending physician, which will depend on factors such as the severity of the disease, the age, weight, and general condition of the patient.

[0286] The compositions administered to a patient may be in the form of pharmaceutical compositions described above. These compositions may be sterilized by conventional sterilization techniques or may be sterile filtered. Aqueous solutions may be packaged for use as is or lyophilized, and the lyophilized preparation is combined with a sterile aqueous carrier prior to administration. The pH of the compound formulation will generally be 3-11, more preferably 5-9, and most preferably 7-8. It will be understood that the use of certain of the above-mentioned excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

[0287] The therapeutic dosage of the compounds or salts of the present disclosure may vary depending, for example, on the particular use for which the treatment is intended, the method of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of the compounds or salts provided herein in a pharmaceutical composition may vary depending on many factors, including dosage, chemical properties (e.g., hydrophobicity), and route of administration. For example, for parenteral administration, the compounds or salts provided herein may be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w / v of the compound or salt. Some common dosage ranges are about 1 μg / kg-body weight to about 1 g / kg-body weight per day. In some embodiments, the dosage range is about 0.01 mg / kg-body weight to about 100 mg / kg-body weight per day. The dosage will often depend on variables such as the type and extent of progression of the disease or disorder, the general health of the particular patient, the relative biological availability of the selected compound, the formulation of excipients, and its route of administration. Effective doses may be extrapolated from dose-response curves derived from in vitro tests or animal model test systems.

[0288] The compounds or salts provided herein can also be formulated in combination with one or more additional active ingredients, which can include any pharmaceutical agent, such as an antiviral agent, a vaccine, an antibody, an immune enhancer, an immunosuppressant, an anti-inflammatory agent, and the like.

[0289] kit The present disclosure also includes pharmaceutical kits useful for treating or preventing, for example, TAM-related diseases or disorders, obesity, diabetes, and other diseases mentioned herein, comprising one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a salt provided herein (e.g., a salt of a compound of Formula I and II). As will be readily apparent to one of skill in the art, such kits may optionally further comprise one or more of a variety of conventional pharmaceutical kit components, such as, for example, a container containing one or more pharma- ceutically acceptable carriers, spare containers, and the like. The kits may also include instructions in the form of packaging materials or labels indicating dosages of the components, directions for administration, and / or directions for mixing the components. EXAMPLES

[0290] The present invention will be described in more detail by specific examples. The following examples are presented for illustrative purposes and are not intended to limit the present invention in any manner. Those skilled in the art will easily recognize various non-critical parameters that can be changed or modified to produce essentially similar results. The compounds of this example have been found to be inhibitors of TAM kinase, as described below.

[0291] General Method Preparative LC-MS purification of some prepared compounds was performed on a Waters mass directed preparative system. The basic instrument settings, protocols, and control software for the operation of these systems are well described in the literature. See, e.g., “Two-Pump At Column Dilution Configuration for Preparative LC-MS”, K. Blom, J. Combi. Chem., 4, 295 (2002); “Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification,” K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem., 5, 670 (2003); and “Preparative LC-MS Purification: Improved Compound Specific Method Optimization,” K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004). The separated compounds are typically subjected to analytical liquid chromatography-mass spectrometry (LCMS) to confirm purity under the following conditions: Instrument: Agilent 1100 Series LC / MSD; Column: Waters Sunfire™ C 18 Particle size 5 μm, 2.1 × 5.0 mm; mobile phase: A: 0.025% TFA in water, B: acetonitrile; gradient: 2% to 80% B in 3 min, flow rate 2.0 mL / min.

[0292] Some of the prepared compounds were also separated on a preparative scale by reversed-phase high-performance liquid chromatography (RP-HPLC) or flash chromatography (silica gel) with an MS detector, as shown in the Examples. Typical preparative reversed-phase high-performance liquid chromatography (RP-HPLC) column conditions are as follows: Purification at pH=2: Waters Sunfire™ C 18 The column was 5 μm in particle size, 19×100 mm, and eluted with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; the flow rate was 30 mL / min, and the separation gradient was optimized for each compound using the Compound Specific Method Optimization protocol described in the literature [see “Preparative LCMS Purification: Improved Compound Specific Method Optimization,” K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used for the 30×100 mm column was 60 mL / min. Purification at pH=10: Waters XBridge C 18 The 5 μm particle size, 19×100 mm column was eluted with mobile phase A: 0.15% NH4OH in water and mobile phase B: acetonitrile; the flow rate was 30 mL / min, and the separation gradient was optimized for each compound using the Compound Specific Method Optimization protocol described in the literature [see “Preparative LCMS Purification: Improved Compound Specific Method Optimization,” K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used for the 30×100 mm column was 60 mL / min.

[0293] Example 1 Synthesis of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate (Compound I maleate, Form I) Scheme 1 [ka] Step 1. 5-Bromo-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine dihydrochloride (compound 2) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, heating mantle, thermocouple, reflux condenser, nitrogen inlet, and nitrogen outlet was charged with tert-butyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (compound 1, 880 g, 2.221 mol) in dichloromethane (DCM, 8.0 L) at room temperature. To this suspension was added a solution of hydrochloric acid in 2-propanol (5.8 N, 2.7 L, 15.66 mol, 7.05 equiv). The mixture was heated to 35° C. After 4 hours, the reaction mixture was diluted with tert-butyl methyl ether (TBME, 4.5 L). The resulting mixture was cooled to room temperature, filtered, and washed with TBME (2.0 L). The cake was dried on the filter under facility vacuum for 24 hours to give 5-bromo-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine dihydrochloride (compound 2, 848 g, 103%) as a light brown solid. 1 H NMR (400 MHz, DMSO-d6) δ 9.53 - 9.29 (m, 3H), 8.23 ​​(s, 1H), 6.91 (s, 1H), 3.38 (tt, J = 11.8, 3.6 Hz, 1H), 3.30 (d, J = 12.4 Hz, 2H), 3.00 (dtd, J = 12.8, 10.1, 2.6 Hz, 2H), 2.07 (dd, J = 14.1, 3.8 Hz, 2H), 1.97 - 1.87 (m, 2H) ppm; 13 C NMR (101 MHz, DMSO-d6) δ 150.34, 139.32, 138.92, 113.24, 109.67, 95.70, 43.06, 30.57, 26.89 ppm;C 11 H 14 BrN5(MW 295.0), LCMS (EI) m / e 296.0 (M+ + H).

[0294] Step 2: 1-(4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 3) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, thermocouple, reflux condenser, nitrogen inlet, and nitrogen outlet was charged with 5-bromo-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine dihydrochloride (compound 2, 1300 g, 3.522 mol) in N-methylpiperidinone (NMP, 10 L) at room temperature. N,N-diisopropylethylamine (1593 g, 12.3 mol) was added to the suspension. The mixture was cooled to 10° C., and then isobutyryl chloride (388 g, 3.645 mol) was charged. The reaction mixture was stirred at room temperature and monitored by HPLC. Additional isobutyryl chloride (22.5 g, 0.211 mol) was added to consume all the starting material. Upon completion of the reaction, the reaction mixture was filtered through a celite pad. The filtrate was cooled to 10° C. and water (26 L) was slowly added to precipitate the product. The solid was collected by filtration and washed with water (12 L). The cake was dried on the filter under utility vacuum for 48 hours to give 1-(4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 3, 1095 g, 85%) as a light brown solid. 1H NMR (400 MHz, DMSO-d6) δ 7.86 (s, 1H), 6.64 (s, 1H), 4.51 (d, J = 12.6 Hz, 1H), 4.01 (d, J = 13.2 Hz, 1H), 3.35 - 3.30 (m, 1H), 3.12 (t, J = 12.3 Hz, 1H), 2.91 - 2.84 (m, 1H), 2.64 (t, J = 12.1 Hz, 1H), 2.02 - 1.93 (m, 2H), 1.55 - 1.42 (m, 2H), 1.02 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H) ppm; 13 C NMR (101 MHz, DMSO-d6) δ 174.50, 155.68, 148.37, 135.22, 111.36, 110.65, 87.27, 45.34, 41.67, 32.91, 31.30, 30.33, 29.49, 20.03, 19.87 ppm;C 15 H 20 BrN5O (MW 365.09), LCMS (EI) m / e 366.1 (M + + H).

[0295] Step 3: 1-(4-(4-amino-5-(4-aminophenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 5) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, heating mantle, thermocouple, reflux condenser, nitrogen inlet, and nitrogen outlet was charged with 1-(4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 3, 700 g, 1.911 mol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (compound 4, 502 g, 2.293 mol), and potassium carbonate (528 g, 3.822 mol) in 1-butanol (7.7 L) and water (1.4 L) at room temperature. To this mixture was added chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (XPhos Pd G2, 90 g, 115 mmol) at room temperature. The reaction mixture was degassed, backfilled with nitrogen and then heated to 80°C. After 2 h at 80°C, n-heptane (8 L) was added to the reaction mixture. The resulting slurry was cooled to room temperature. The solid was collected by filtration and washed with water (6 L). The cake was dried on the filter under facility vacuum for 72 h to give 1-(4-(4-amino-5-(4-aminophenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 5, 648 g, 90%) as a brown solid. 1H NMR (500 MHz, DMSO-d6) δ 7.85 (s, 1H), 7.09 (d, J = 8.4 Hz, 2H), 6.65 (d, J = 8.4 Hz, 2H), 6.43 (s, 1H), 5.24 (s, 2H), 4.53 (d, J = 12.6 Hz, 1H), 4.04 (d, J = 13.1 Hz, 1H), 3.38 (ddd, J = 11.8, 8.2, 3.8 Hz, 1H), 3.16 (t, J = 12.7 Hz, 1H), 2.87 (p, J = 6.7 Hz, 1H), 2.71 - 2.66 (m, 1H), 2.08 - 2.00 (m, 2H), 1.61 - 1.58 (m, 2H), 1.02 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H) ppm; 13 C NMR (126 MHz, DMSO-d6) δ 174.51, 156.31, 148.51, 147.65, 133.98, 130.35, 122.57, 119.37, 114.57, 109.67, 108.85, 45.48, 41.81, 32.97, 31.50, 30.56, 29.50, 20.06, 19.89 ppm;C 21 H 26 N6O (MW 378.48), LCMS (EI) m / e 379.2 (M + + H).

[0296] Step 4. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (compound I) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, thermocouple, nitrogen inlet, and nitrogen outlet was charged with 1-(4-(4-amino-5-(4-aminophenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 5, 944 g, 2.494 mol) and 1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate hydrochloride (compound 6, 801 g, 2.569 mol) in tetrahydrofuran (THF, 10 L) at room temperature. Triethylamine (NEt3, 0.695 L, 4.988 mol) was added to the reaction mixture. Upon completion of the reaction, the reaction mixture was divided equally into two 22 L round bottom flasks. Each flask was charged with water (8 L) at room temperature. The solids were collected by filtration. The resulting wet cake was transferred back to a 22 L round bottom flask. The flask was charged with THF (3.2 L) and water (10.5 L). The slurry was heated to 55° C. and stirred at 55° C. for 2 h. The solids were collected by filtration at 30° C. and washed with water (8 L). The cake was dried on the filter under facility vacuum for 72 h to give N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound I, 1425 g, 90%) as a light brown solid. 1H NMR (500 MHz, DMSO-d6) δ 10.82 (s, 1H), 8.71(s, 1H), 8.64 (ddd, J = 4.8, 1.8, 0.8 Hz, 1H), 8.06 (td, J = 7.7, 1.9 Hz, 1H), 7.91 (s, 1H), 7.77 (d, J = 8.6 Hz, 2H), 7.60 - 7.53 (m, 2H), 7.43 (d, J = 8.6 Hz, 2H), 6.58 (s, 1H), 4.78 (hept, J = 6.8 Hz, 1H), 4.54 (d, J = 12.3 Hz, 1H), 4.06 (d, J = 12.5 Hz, 1H), 3.40 (tt, J = 11.7, 3.5 Hz, 1H), 3.20 (t, J = 12.3 Hz, 1H), 2.91 (hept, J = 6.7 Hz, 1H), 2.69 (t, J = 12.3 Hz, 1H), 2.06 (dd, J = 27.7, 12.3 Hz, 2H), 1.61 (q, J = 11.8 Hz, 1H), 1.55 - 1.47 (m, 1H), 1.44 (d, J = 6.8 Hz, 6H), 1.02 (d, J = 6.8 Hz, 3H), 1.00 (d, J = 6.8 Hz, 3H) ppm; 13 C NMR (126 MHz, DMSO-d6) δ 174.51, 163.02, 160.31, 156.20, 150.18, 149.98, 149.18, 148.08, 147.79, 139.55, 137.51, 134.45, 131.24, 130.23, 125.09, 124.57, 120.46, 117.98, 109.90, 109.35, 105.27, 51.17, 45.46, 41.79, 32.97, 31.48, 30.54, 29.49, 21.09 (2 -CH3), 20.07, 19.89 ppm;C 34 H 37 N9O4(MW 635.73), LCMS (EI) m / e 636.3 (M + + H)。

[0297] Step 5. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate (Compound I maleate, Form I) A 50 L reactor equipped with a mechanical stirrer, heating jacket, thermocouple, reflux condenser, nitrogen inlet, and nitrogen outlet was charged with N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (compound I, 1401 g, 2.204 mol) in methanol (MeOH, 10 L) and dichloromethane (DCM, 20 L) at room temperature. The slurry was heated to 50° C. to form a solution. Activated carbon (70 g) and silica gel (70 g) were added to the solution. After stirring at 50° C. for 2 hours, the mixture was filtered through a celite pad. To the filtrate was added maleic acid (269 g, 2.314 mol). Most of the DCM was distilled off at atmospheric pressure. A solid gradually precipitated. The solid was collected by filtration at 18° C. and washed with MeOH (3 L). The cake was dried on the filter under facility vacuum for 72 h to give N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate (compound I maleate, 1425 g, 86%) as an off-white solid. 11H NMR (400 MHz, DMSO-d6) δ 10.83 (s, 1H), 8.71 (s, 1H), 8.65 - 8.63 (m, 1H), 8.06 (td, J = 7.8, 1.9 Hz, 1H), 7.95 (s, 1H), 7.77 (d, J = 8.6 Hz, 2H), 7.58 - 7.55 (m, 2H), 7.44 (d, J = 8.5 Hz, 2H), 6.62 (s, 1H), 6.25 (s, 2H), 4.78 (hept, J = 6.7 Hz, 1H), 4.54 (d, J = 12.3 Hz, 1H), 4.06 (d, J = 12.5 Hz, 1H), 3.40 (tt, J = 11.6, 3.2 Hz, 1H), 3.20 (t, J = 12.3 Hz, 1H), 2.90 (hept, J = 6.6 Hz, 1H), 2.69 (t, J = 12.1 Hz, 1H), 2.09 -2.01 (m, 2H), 1.65 - 1.57 (m, 1H), 1.56 - 1.49 (m, 1H), 1.44 (d, J = 6.8 Hz, 6H), 1.02 (d, J = 5.5 Hz, 3H), 1.00 (d, J = 5.5 Hz, 3H) ppm; 13 13C NMR (101 MHz, DMSO) δ 174.52, 167.21, 163.03, 160.33, 155.20, 150.18, 149.99, 149.18, 148.07, 146.26, 139.55, 137.67, 135.32, 131.34, 130.87, 130.22, 125.09, 124.57, 120.49, 119.30, 109.80, 109.47, 105.26, 51.17, 45.43, 41.76, 32.97, 31.45, 30.53, 29.50, 21.09 (2 -CH3), 20.06, 19.89 ppm; 34 1H 37 C9H9N9O4 (free base, MW 635.73), LCMS (EI) m / e 636.3 (M + + H).

[0298] Example 2 Synthesis of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate (amorphous) (Compound II hemisulfate) Scheme 2 [ka] Step 1. 5-Bromo-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine dihydrochloride (compound 2) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, heating mantle, thermocouple, reflux condenser, nitrogen inlet, and nitrogen outlet was charged with tert-butyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (compound 1, 880 g, 2.221 mol) in dichloromethane (DCM, 8.0 L) at room temperature. To this suspension was added a solution of hydrochloric acid in 2-propanol (5.8 N, 2.7 L, 15.66 mol, 7.05 equiv). The mixture was heated at 35° C. for 4 hours. The reaction mixture was diluted with tert-butyl methyl ether (TBME, 4.5 L) and cooled to room temperature. The slurry was filtered and washed with TBME (2.0 L). The cake was dried on the filter under facility vacuum for 24 hours to give 5-bromo-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine dihydrochloride (compound 2, 848 g, 103%) as a light brown solid. 1 H NMR (400 MHz, DMSO-d6) δ 9.53 - 9.29 (m, 3H), 8.23 ​​(s, 1H), 6.91 (s, 1H), 3.38 (tt, J = 11.8, 3.6 Hz, 1H), 3.30 (d, J = 12.4 Hz, 2H), 3.00 (dtd, J = 12.8, 10.1, 2.6 Hz, 2H), 2.07 (dd, J = 14.1, 3.8 Hz, 2H), 1.97 - 1.87 (m, 2H) ppm; 13C NMR (101 MHz, DMSO-d6) δ 150.34, 139.32, 138.92, 113.24, 109.67, 95.70, 43.06, 30.57, 26.89 ppm;C 11 H 14 BrN5(MW 295.0), LCMS (EI) m / e 296.0 (M + + H).

[0299] Step 2: 1-(4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 3) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, thermocouple, reflux condenser, nitrogen inlet, and nitrogen outlet was charged with 5-bromo-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine dihydrochloride (compound 2, 1300 g, 3.522 mol) in N-methylpiperidinone (NMP, 10 L) at room temperature. To this suspension was added N,N-diisopropylethylamine (1593 g, 12.3 mol). The mixture was cooled to 10° C. and treated with isobutyryl chloride (388 g, 3.645 mol). The reaction mixture was stirred while warming to room temperature and monitored by HPLC. Additional isobutyryl chloride (22.5 g, 0.211 mol) was added to consume all the starting material. Upon completion of the reaction, the reaction mixture was filtered through a celite pad. The filtrate was cooled to 10° C. and water (26 L) was slowly added to precipitate the product. The solid was collected by filtration and washed with water (12 L). The cake was dried on the filter under vacuum for 48 hours to give 1-(4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 3, 1095 g, 85%) as a light brown solid. 1H NMR (400 MHz, DMSO-d6) δ 7.86 (s, 1H), 6.64 (s, 1H), 4.51 (d, J = 12.6 Hz, 1H), 4.01 (d, J = 13.2 Hz, 1H), 3.35 - 3.30 (m, 1H), 3.12 (t, J = 12.3 Hz, 1H), 2.91 - 2.84 (m, 1H), 2.64 (t, J = 12.1 Hz, 1H), 2.02 - 1.93 (m, 2H), 1.55 - 1.42 (m, 2H), 1.02 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H) ppm; 13 C NMR (101 MHz, DMSO-d6) δ 174.50, 155.68, 148.37, 135.22, 111.36, 110.65, 87.27, 45.34, 41.67, 32.91, 31.30, 30.33, 29.49, 20.03, 19.87 ppm;C 15 H 20 BrN5O (MW 365.09), LCMS (EI) m / e 366.1 (M + + H).

[0300] Step 3: 1-(4-(4-amino-5-(4-aminophenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 5) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, heating mantle, thermocouple, reflux condenser, nitrogen inlet, and nitrogen outlet was charged with 1-(4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 3, 700 g, 1.911 mol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (compound 4, 502 g, 2.293 mol), and potassium carbonate (528 g, 3.822 mol) in 1-butanol (7.7 L) and water (1.4 L) at room temperature. The mixture was treated with chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (XPhos Pd G2, 90 g, 115 mmol) at room temperature. The reaction mixture was degassed, backfilled with nitrogen and then heated to 80°C. After 2 h at 80°C, the reaction mixture was diluted with n-heptane (8 L). The resulting slurry was cooled to room temperature. The solid was collected by filtration and washed with water (6 L). The cake was dried on the filter under vacuum for 72 h to give 1-(4-(4-amino-5-(4-aminophenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 5, 648 g, 90%) as a brown solid. 1H NMR (500 MHz, DMSO-d6) δ 7.85 (s, 1H), 7.09 (d, J = 8.4 Hz, 2H), 6.65 (d, J = 8.4 Hz, 2H), 6.43 (s, 1H), 5.24 (s, 2H), 4.53 (d, J = 12.6 Hz, 1H), 4.04 (d, J = 13.1 Hz, 1H), 3.38 (ddd, J = 11.8, 8.2, 3.8 Hz, 1H), 3.16 (t, J = 12.7 Hz, 1H), 2.87 (p, J = 6.7 Hz, 1H), 2.71 - 2.66 (m, 1H), 2.08 - 2.00 (m, 2H), 1.61 - 1.58 (m, 2H), 1.02 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H) ppm; 13 C NMR (126 MHz, DMSO-d6) δ 174.51, 156.31, 148.51, 147.65, 133.98, 130.35, 122.57, 119.37, 114.57, 109.67, 108.85, 45.48, 41.81, 32.97, 31.50, 30.56, 29.50, 20.06, 19.89 ppm;C 21 H 26 N6O (MW 378.48), LCMS (EI) m / e 379.2 (M + + H).

[0301] Step 4. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (compound II) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, thermocouple, nitrogen inlet, and nitrogen outlet was charged with 1-(4-(4-amino-5-(4-aminophenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 5, 450 g, 1.189 mol) and 1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (compound 7, 342 g, 1.248 mol) in tetrahydrofuran (THF, 5 L) at room temperature. The reaction mixture was treated successively with triethylamine (NEt3, 241 g, 2.278 mol) followed by 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate (V) (HATU, 565 g, 1.486 mol). Upon completion of the reaction, water (8 L) was added to the reaction mixture at room temperature. The solid was collected by filtration. The resulting wet cake was transferred back to a 22 L round bottom flask and slurried with THF (2.7 L) and water (5.4 L). The slurry was heated to 55° C. and stirred at 55° C. for 2 h. After cooling to 30° C., the solid was collected by filtration and washed with water (8 L). The cake was dried on the filter under vacuum for 2 days to give N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound II, 717 g, 95%) as a light brown solid. 1H NMR (500 MHz, DMSO-d6) δ 11.03 (s, 1H), 8.68 (s, 1H), 8.19 (s, 1H), 7.82 (d, J = 8.6 Hz, 2H), 7.55 - 7.46 (m, 5H), 7.38 - 7.36 (m, 2H), 6.85 (s, 1H), 4.79 (hept, J = 6.8 Hz, 1H), 4.55 (d, J = 12.3 Hz, 1H), 4.08 (d, J = 12.9 Hz, 1H), 3.43 (tt, J = 11.8, 3.5 Hz, 1H), 3.21 (t, J = 12.4 Hz, 1H), 2.90 (hept, J = 6.7 Hz, 1H), 2.70 (t, J = 12.2 Hz, 1H), 2.02 (dd, J = 23.0, 13.5 Hz, 2H), 1.66 (q, J = 11.8, 11.3 Hz, 1H), 1.53 (q, J = 12.2, 11.7 Hz, 1H), 1.44 (d, J = 6.8 Hz, 6H), 1.03 (d, J = 7.0 Hz, 3H), 1.01 (d, J = 7.0 Hz, 3H) ppm; 13 C NMR (126 MHz, DMSO-d6) δ 174.55, 163.26, 160.65, 152.60, 150.48, 147.46, 142.27, 138.14, 137.56, 135.87, 130.21, 129.89, 129.50, 129.12, 129.05, 122.72, 120.55, 111.00, 108.35, 105.10, 50.94, 45.35, 41.67, 32.98, 31.40, 30.50, 29.49, 21.19 (2 -CH3), 20.06, 19.89 ppm;C 35 H 38 N8O4(MW 634.74), LCMS (EI) m / e 635.3 (M + + H)。

[0302] Step 5. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate (compound II hydrochloride) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, thermocouple, nitrogen inlet, and nitrogen outlet was charged with N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (compound II, 713 g, 1.123 mol) in methanol (MeOH, 5.6 L) at room temperature. The mixture was heated to 55° C. and treated with a solution of sulfuric acid (H2SO4, 116 g, 1.179 mol) in water (1 L). After stirring at 55° C. for 30 min, 2.8 L of the solvent was distilled off under reduced pressure. The reaction mixture was cooled to room temperature. The resulting solid was collected by filtration and washed with MeOH (0.7 L). The cake was dried on the filter under vacuum for 2 days to give N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate (Compound II hydrochloride, 744 g, 90%) as a yellow solid.

[0303] Step 6. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate (compound II hemisulfate) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, thermocouple, nitrogen inlet, and nitrogen outlet was charged with N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate (Compound II hydrochloride, 729 g, 0.995 mol) in water (16 L) at room temperature. The slurry was heated to 35° C. and stirred for 3 days. The solid was collected by filtration and washed with water (10 L). The wet cake was dried on the filter under vacuum to give N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate (Compound II hemisulfate, 644 g, 95%) as an off-white solid.

[0304] Step 7 N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate, amorphous A 2 L round bottom flask was charged with N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate (compound II hemisulfate, 40 g, 58.5 mmol) in acetone (500 mL) and methanol (500 mL) at room temperature. The solution was filtered through filter paper into a 3 L round bottom flask. The filtrate was concentrated under reduced pressure to remove most of the solvent. The resulting foamed solid was dried under facility vacuum in a 50° C. vacuum oven with a nitrogen sweep to give N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate (amorphous hemisulfate salt of Compound II, 38 g, 95%) as a pale yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 11.01 (s, 1H), 8.68 (s, 1H), 8.07 (s, 1H), 7.80 (d, J = 8.6 Hz, 2H), 7.55 - 7.45 (m, 5H), 7.38 - 7.36 (m, 2H), 6.74 (s, 1H), 4.79 (hept, J = 6.8 Hz, 1H), 4.55 (d, J = 12.3 Hz, 1H), 4.07 (d, J = 13.0 Hz, 1H), 3.42 (tt, J = 11.8, 3.3 Hz, 1H), 3.24 - 3.18 (m, 1H), 2.91 (hept, J = 6.7 Hz, 1H), 2.70 (t, J = 12.0 Hz, 1H), 2.07 - 1.99 (m, 2H), 1.68 - 1.51 (m, 2H), 1.44 (d, J = 6.8 Hz, 6H), 1.03 (d, J = 7.0 Hz, 3H), 1.01 (d, J = 7.0 Hz, 3H) ppm; 13C NMR (101 MHz, DMSO-d6) δ 174.55, 163.26, 160.65, 152.60, 150.48, 147.46, 142.28, 138.14, 137.56, 135.87, 130.21, 129.89, 129.50, 129.12, 129.05, 122.72, 120.55, 111.00, 108.35, 105.10, 50.94, 45.35, 41.67, 32.98, 31.40, 30.50, 29.49, 21.19 (2 -CH3), 20.06, 19.89 ppm;C 35 H 38 N8O4(MW 634.74), LCMS (EI) m / e 635.3 (M + + H); acid titration, sulfate:free base = 0.50; elemental analysis of sulfur, calculated 2.34%, found 2.29%.

[0305] Example 3: Alternative synthesis of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (compound II) Scheme 3 [ka] Step 1 1-Isopropyl-2,4-dioxo-3-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (compound 8) A 5 L four-neck round bottom flask equipped with a mechanical stirrer, thermocouple, nitrogen inlet, and nitrogen outlet was charged with 1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (compound 7, 202 g, 0.736 mol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (169 g, 0.773 mol) in N,N-dimethylformamide (DMF, 1.2 L) at room temperature. To this mixture was added 2-(3H-[1,2,3]triazolo[4,5-b]]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate (V) (HATU, 336 g, 0.884 mmol) at room temperature. After cooling to an internal temperature below 15°C, triethylamine (NEt3, 97 g, 0.957 mol) was added to the mixture. The reaction mixture was then stirred at 15-25°C for 4 h. Water (1.2 L) was added slowly to precipitate the product. The solid was collected by filtration and washed with water (3 x 0.6 L). The cake was dried in a vacuum oven at 50°C with a gentle sweep of nitrogen to give 1-isopropyl-2,4-dioxo-3-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (compound 8, 363 g, 104%) as a white solid. 1 H NMR (600 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.65 (s, 1H), 7.68 - 7.63 (m, 4H), 7.53 - 7.51 (m, 2H), 7.48 - 7.45 (m, 1H), 7.36 (dd, J = 8.2, 1.2 Hz, 2H), 4.78 (hept, J = 6.8 Hz, 1H), 1.43 (d, J = 6.8 Hz, 6H), 1.29 (s, 12H) ppm; 13C NMR (150 MHz, DMSO-d6) δ 163.24, 160.69, 150.46, 147.50, 141.32, 135.96, 135.83, 129.47, 129.09, 129.03, 124.09, 119.19, 105.10, 83.98, 50.89, 25.14, 21.18 ppm;C 26 H 30 BN3O5(MW 475.35), LCMS (EI) m / e 476.3 (M + + H).

[0306] Step 2: tert-butyl 4-(4-amino-5-(4-(1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (compound 9) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, reflux condenser, thermocouple, heating mantle, nitrogen inlet, and nitrogen outlet was charged with tert-butyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (compound 1, 557 g, 1.406 mol), 1-isopropyl-2,4-dioxo-3-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (compound 8, 735 g, 1.546 mol), and tripotassium phosphate (KPO, 597 g, 2.811 mol) in 1,4-dioxane (6.0 L) and water (1.1 L) at room temperature. The mixture was degassed and backfilled with nitrogen. Chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (XPhos Pd G2, 77 g, 98 mmol) was added to the reaction mixture. The reaction mixture was degassed, backfilled with nitrogen and heated to 80°C. After stirring at 80°C for 3 h, water (6.0 L) was added to the reaction mixture over 1 h. The resulting solid was collected by filtration at 20°C and washed with water (2 x 3.0 L) and n-heptane (2 x 2.0 L). The cake was returned to a 22 L round bottom flask and slurried in ethyl acetate (EtOAc, 6.0 L) and methyl tert-butyl ether (MTBE, 2.2 L) at room temperature. The suspension was heated to 55°C and stirred for 2 h. After the mixture was cooled to 20° C., the solid was collected by filtration and washed with MTBE (2×1.0 L). The cake was dried under vacuum on the filter funnel for 2 days to give tert-butyl 4-(4-amino-5-(4-(1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (Compound 9, 827 g, 85%) as a light brown solid. 1H NMR (500 MHz, DMSO-d6) δ 10.97 (s, 1H), 8.67 (s, 1H), 7.90 (s, 1H), 7.78 (d, J = 8.6 Hz, 2H), 7.54 (t, J = 7.5 Hz, 2H), 7.48 - 7.46 (m, 1H), 7.43 (d, J = 8.6 Hz, 2H), 7.38 - 7.36 (m, 2H), 6.58 (s, 1H), 4.79 (hept, J = 6.7 Hz, 1H), 4.08 - 4.03 (m, 2H), 3.34 - 3.28 (m, 1 H), 2.89 (s, 2H), 1.99 (d, J = 11.4 Hz, 2H), 1.56 (qd, J = 12.7, 4.1 Hz, 2H), 1.44 (d, J = 6.8 Hz, 6H), 1.42 (s, 9H) ppm; 13 C NMR (126 MHz, DMSO-d6) δ 163.25, 160.57, 156.20, 154.33, 150.49, 147.78, 147.40, 135.56, 135.89, 134.56, 131.20, 130.24, C 36 H 40 N8O5(MW 664.76), LCMS (EI) m / e 665.3 (M + + H).

[0307] Step 3. N-(4-(4-amino-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide dihydrochloride (compound 10) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, reflux condenser, thermocouple, heating mantle, nitrogen inlet, and nitrogen outlet was charged with tert-butyl 4-(4-amino-5-(4-(1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (compound 9, 737 g, 1.053 mol) in dichloromethane (DCM, 4.5 L) at room temperature. To this suspension was added a solution of hydrochloric acid in 2-propanol (5.8 N in IPA, 1.474 L, 8.549 mol, 8.12 equiv). The mixture was heated to 35-40° C. After 3 h at 35-40° C., the reaction mixture was cooled to 15° C. Water (0.4 L) was added and the mixture was stirred at 15° C. for 1 h. The mixture was diluted with DCM (9.0 L). The solid was collected by filtration and washed with DCM (2×0.2 L). The cake was dried under vacuum on the filter funnel for 2 days to give N-(4-(4-amino-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide dihydrochloride (630 g, 94%) as a needle-like solid. 1 H NMR (500 MHz, DMSO-d6) δ 11.03 (s, 1H), 9.31 - 9.21 (m, 3H), 8.68 (s, 1H), 8.29 (s, 1H), 7.83 (d, J = 8.7 Hz, 2H), 7.55 - 7.46 (m, 5H), 7.38 - 7.37 (m, 2H), 6.80 (s, 1H), 4.83 (hept, J = 6.8 Hz, 1H), 3.50 (tt, J = 11.7, 3.4 Hz, 1H), 3.35 (d, J = 12.4 Hz, 2H), 3.08 (q, J = 12.5 Hz, 2H), 2.18 - 2.15 (m, 2H), 1.99 - 1.96 (m, 2H), 1.44 (d, J = 6.8 Hz, 6H) ppm; 13C NMR (126 MHz, DMSO-d6) δ 163.26, 160.70, 150.47, 150.38, 147.52, 138.68, 138.59, 138.06, 135.86, 130.21, 129.50, 129.12, 129.05, 128.76, 126.12, 120.66, 111.81, 107.49, 105.09, 50.96, 43.19, 30.65, 27.07, 21.19 ppm;C 31 H 32 N8O3(MW 564.64), LCMS (EI) m / e 565.3 (M + + H).

[0308] Step 4. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (compound II) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, thermocouple, nitrogen inlet, and nitrogen outlet was charged with N-(4-(4-amino-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide dihydrochloride (608 g, 0.954 mol) in dichloromethane (DCM, 17.6 L) at room temperature. Aqueous sodium hydroxide (NaOH, 1N, 3.815 L, 3.815 mol) was added to the suspension. After stirring at room temperature for 1 hour, the mixture was cooled to 0-5° C. and treated with isobutyryl chloride (107 g, 1.001 mol). The reaction mixture was stirred at room temperature for 24 hours. Upon completion of the reaction, the mixture was filtered through a pad of Celite. The organic phase was separated, washed with water (2×2.5 L) and concentrated under reduced pressure. To the residue was added DCM (2.4 L) and methyl tert-butyl ether (MTBE, 9.7 L). The mixture was heated to 50° C. and stirred for 1 h. After cooling to room temperature, the resulting solid was collected by filtration. The cake was dried on the filter under vacuum for 24 h to give N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (compound II, 548 g, 91%) as a pale yellow solid. 1H NMR (500 MHz, DMSO-d6) δ 11.03 (s, 1H), 8.68 (s, 1H), 8.19 (s, 1H), 7.82 (d, J = 8.6 Hz, 2H), 7.55 - 7.46 (m, 5H), 7.38 - 7.36 (m, 2H), 6.85 (s, 1H), 4.79 (hept, J = 6.8 Hz, 1H), 4.55 (d, J = 12.3 Hz, 1H), 4.08 (d, J = 12.9 Hz, 1H), 3.43 (tt, J = 11.8, 3.5 Hz, 1H), 3.21 (t, J = 12.4 Hz, 1H), 2.90 (hept, J = 6.7 Hz, 1H), 2.70 (t, J = 12.2 Hz, 1H), 2.02 (dd, J = 23.0, 13.5 Hz, 2H), 1.66 (q, J = 11.8, 11.3 Hz, 1H), 1.53 (q, J = 12.2, 11.7 Hz, 1H), 1.44 (d, J = 6.8 Hz, 6H), 1.03 (d, J = 7.0 Hz, 3H), 1.01 (d, J = 7.0 Hz, 3H) ppm; 13 C NMR (126 MHz, DMSO-d6) δ 174.55, 163.26, 160.65, 152.60, 150.48, 147.46, 142.27, 138.14, 137.56, 135.87, 130.21, 129.89, 129.50, 129.12, 129.05, 122.72, 120.55, 111.00, 108.35, 105.10, 50.94, 45.35, 41.67, 32.98, 31.40, 30.50, 29.49, 21.19 (2 -CH3), 20.06, 19.89 ppm;C 35 H 38 N8O4(MW 634.74), LCMS (EI) m / e 635.3 (M + + H)。

[0309] Example 4 Synthesis of tert-butyl 4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (Compound 1 in Schemes 1 and 2) Scheme 4 [ka] Step 1: tert-Butyl 4-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5,6-dihydropyridine-1(2H)-carboxylate (compound 13) A 3 L round bottom flask equipped with a mechanical stirrer, heating mantle, thermocouple, reflux condenser, nitrogen inlet, and nitrogen outlet was charged with 7-bromopyrrolo[1,2-f][1,2,4]triazine-4-amine (compound 11, 100 g, 469 mmol) and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (compound 12, 174 g, 563 mmol) in 1,4-dioxane (876 mL) at room temperature. Potassium carbonate (130 g, 939 mmol) and water (218 g) were added sequentially to the reaction flask. The mixture was degassed by exposure to vacuum and backfilled with nitrogen atmosphere three times. After addition of tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4, 13.56 g, 11.7 mmol), the reaction mixture was degassed and backfilled with nitrogen three times at room temperature. The reaction mixture was then heated to 85-90 °C and stirred at that temperature for 16 h. Upon completion of the reaction, water (900 mL) was added in 30 min while the internal temperature was above 50 °C. The mixture was cooled to room temperature. A solid gradually precipitated. The solid was collected by filtration at 18 °C and washed with water (2 x 250 mL) and methyl tert-butyl ether (MTBE, 3 x 200 mL). The wet cake was returned to the reaction flask and stirred in MTBE (750 mL) at 50 °C for 1 h. The solid was collected by filtration at room temperature. The cake was dried in a vacuum oven at 50° C. with a nitrogen sweep for 72 hours to give tert-butyl 4-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5,6-dihydropyridine-1(2H)-carboxylate (compound 13, 123.7 g, 84%) as a brown solid. 1 H NMR (500 MHz, DMSO-d6) δ 7.89 (s, 1H), 7.69 (s, 2H), 7.00 (s, 1H), 6.91 (d, J = 4.6 Hz, 1 H), 6.69 (d, J = 4.5 Hz, 1H), 4.06 (s, 2H), 3.55 (t, J = 5.5 Hz, 2H), 2.59 - 2.52 (m, 2H), 1.43 (s, 9H) ppm;C 16 H21 N5O2(MW 315.37), LCMS (EI) m / e 316.1 (M + + H).

[0310] Step 2: tert-Butyl 4-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (compound 14) A 2-L flask was charged with tert-butyl 4-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5,6-dihydropyridine-1(2H)-carboxylate (compound 13, 50.0 g, 159 mmol) and platinum(IV) oxide (10.0 g, 44 mmol) in acetic acid (1000 mL) at room temperature. The flask was placed on a Parr Shaker under 50 psi of hydrogen gas. After 16 h, the reaction mixture was filtered through a Celite pad (50 g) and washed with methanol (500 mL). The filtrate was concentrated under reduced pressure. To the residue was added methyl tert-butyl ether (MTBE, 600 mL) at room temperature. A solution of potassium carbonate (ca. 50 g) in water (1200 mL) was added to the MTBE solution to adjust the pH value to 6-7. The solid was collected by filtration and washed with water (2×300 mL) and n-heptane (2×300 mL). The cake was dried in a vacuum oven at 50° C. with a nitrogen sweep for 16 hours to give tert-butyl 4-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (compound 14, 49.3 g, 98%) as a light brown solid. 1 H NMR (500 MHz, DMSO-d6) δ 7.82 (s, 1H), 7.59 (s, 2H), 6.81 (d, J = 4.4 Hz, 1H), 6.44 (d, J = 4.3 Hz, 1H), 4.05 (d, J = 11.3 Hz, 2H), 3.25 (tt, J = 11.8, 3.3 Hz, 1H), 2.88 (s, 2H), 1.95 (d, J = 11.9 Hz, 2H), 1.51 (qd, J = 12.6, 4.0 Hz, 2H), 1.42 (s, 9H) ppm;C 16 H 23N5O2(MW 317.39), LCMS (EI) m / e 318.1 (M + + H).

[0311] Step 3: tert-Butyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (compound 1) A 22 L five-neck round bottom flask equipped with a mechanical stirrer, thermocouple, reflux condenser, nitrogen inlet, and nitrogen outlet was charged with tert-butyl 4-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (compound 14, 730 g, 2.30 mol) in tetrahydrofuran (THF, 14.0 L) at room temperature. The mixture was cooled to 0-5° C. N-bromosuccinimide (NBS, 409 g, 2.30 mol) was added to the reaction mixture over 5 min while maintaining the internal temperature below 15° C. After stirring at below 10° C. for 1 h, some of the solvent (9.0 L) was removed under reduced pressure. To the remaining solution was added a solution of sodium bicarbonate (140 g, 1.67 mol) in water (14.0 L) over 5 min. A solid precipitated. The solid was collected by filtration and washed with water (7.0 L) and n-heptane (4 L). The wet cake was dried on the filter under utility vacuum for 48 hours to give tert-butyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (compound 1, 886 g, 97%) as a brown solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.86 (s, 1H), 6.66 (s, 1H), 4.04 (d, J = 11.0 Hz, 2H), 3.30-3.23 (m, 1H), 2.86 (br.s, 2H), 1.92 (d, J = 12.4 Hz, 2H), 1.50 (qd, J = 12.8, 4.1 Hz, 2H), 1.41 (s, 9H) ppm; 13C NMR (101 MHz, DMSO-d6) δ 155.68, 154.29, 148.35, 135.37, 111.31, 110.68, 87.29, 79.10, 43.97, 32.63, 30.37, 28.58 ppm;C 16 H 22 BrN5O2(MW 395.10), LCMS (EI) m / e 396.1 (M + + H).

[0312] Example 5 1-Isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Compound 7 in Schemes 2 and 3) Step 1 Diethyl 2-((3-phenylureido)methylene)malonate [ka] To a mixture of diethyl (aminomethylene)malonate (6.0 g, 32 mmol) and phenyl isocyanate (3.8 mL, 35 mmol) in 1,2-dichloroethane (20 mL) was added N,N-diisopropylethylamine (7.2 mL, 42 mmol) at room temperature. The reaction mixture was then stirred at 70° C. overnight, cooled to room temperature, Et2O (50 mL) was added, and stirred for an additional 30 min. The resulting solid was collected by filtration, washed with ether, and dried to give the product as a white solid (4.88 g, 50%). LCMS C 15 H 19 N2O5(M+H) + Calculated for: m / z = 307.1. Found: 307.2.

[0313] Step 2 Ethyl 2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate [ka] Diethyl 2-((3-phenylureido)methylene)malonate (4.88 g, 15.9 mmol) from the previous step and 2.5 M NaOEt in EtOH (13 mL, 32 mmol) were stirred at room temperature for 1 h in EtOH (20 mL). The resulting mixture was diluted with EtOAc, washed / acidified with 1N citric acid, washed with water, brine, dried over Na2SO4, and concentrated to give the crude product as a white solid, which was used directly in the next step (4.1 g, 99%). LCMS C 13 H 13 N2O4(M+H) + Calculated for: m / z = 261.1. Found: 261.1.

[0314] Step 3: 1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate ethyl [ka] A mixture of ethyl 2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate from the previous step (1.50 g, 5.76 mmol), isopropyl iodide (1.2 mL, 12 mmol), and Cs2CO3 (5.6 g, 17 mmol) in DMF (20 mL) was stirred at 50 °C for 5 h. The reaction mixture was then cooled to room temperature, diluted with EtOAc, washed with water, brine, dried over Na2SO4, and concentrated to give the crude product, which was used directly in the next step. LCMS C 16 H 19 N2O4(M+H) + Calculated for: m / z = 303.1. Found: 303.1.

[0315] Step 4 1-Isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid [ka] A mixture of ethyl 1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1.70 g, 5.62 mmol) from the previous step in 4.0 M HCl in 1,4-dioxane (9.8 mL, 39 mmol) and water (2.1 mL) was stirred at 60° C. for 4 h, cooled to room temperature and water was added. The resulting solid was then filtered (washed with water) to give the product as a white solid (1.1 g, 71%). LCMS C 14 H 15 N2O4(M+H) + Calculated for: m / z = 275.1. Found: 275.1.

[0316] Example 6 Synthesis of 1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (compound 6 in Scheme 1) Step 1 Diethyl 2-((3-pyridin-2-ylureido)methylene)malonate [ka] To a mixture of diethyl 2-(aminomethylene)malonate (3.0 g, 16.0 mmol) and 2-isocyanatopyridine (2.02 g, 16.8 mmol) in 1,2-dichloroethane (9.0 mL) at room temperature was added N,N-diisopropylethylamine (3.6 mL, 20.8 mmol). The reaction mixture was then stirred at 70° C. overnight, cooled to room temperature, and directly purified by column chromatography (0% to 15% MeOH in CH2Cl2) to give the product (3.18 g, 65%). LCMS C 14 H 18 N3O5(M+H) + Calculated for: m / z = 308.1. Found: 308.1.

[0317] Step 2 1-Isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid [ka] A mixture of diethyl 2-((3-(pyridin-2-yl)ureido)methylene)malonate (3.18 g, 10.4 mmol) and 2.5 M NaOEt in EtOH (6.2 mL, 15.5 mmol) was stirred at room temperature for 3 h. The resulting mixture was diluted with EtOAc and washed / acidified with 1N citric acid solution (30 mL). The organic layer was separated and the aqueous layer was further extracted with 3:1 CHCl3 / isopropyl alcohol (30 mL x 3). The combined organic layers were dried over Na2SO4 and concentrated to give the crude product ethyl 2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate, which was used directly in the next step. LCMS C 12 H 12 N3O4(M+H) + Calculated for: m / z = 262.1. Found: 262.2.

[0318] A mixture of crude ethyl 2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2.06 mL, 20.7 mmol) from the previous step and Cs2CO3 (10.1 g, 31.0 mmol) in DMF (35 mL) was stirred at 70° C. for 3 h. The reaction mixture was then cooled to room temperature, diluted with 3:1 CHCl3 / isopropyl alcohol (75 mL), washed with water, brine, dried over Na2SO4, and concentrated to give the crude product, ethyl 1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate, which was used directly in the next step. LCMS C 15 H 18 N3O4(M+H) + Calculated for: m / z = 304.1. Found: 304.1.

[0319] A mixture of the crude ethyl 1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate from the previous step in 4M HCl in 1,4-dioxane (20 mL, 82 mmol) and water (5.0 mL) was stirred at 80° C. for 5 h, cooled to room temperature, and concentrated. The resulting material was then purified by column chromatography (0% to 15% MeOH in CH2Cl2) to give the product as a slightly yellowish solid (1.50 g, 47% for three steps). LCMS C 13 H 14 N3O4(M+H) + Calculated for: m / z = 276.1. Found: 276.1.

[0320] Example 7 Solid-State Characterization of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide Maleate (Compound I Maleate, Form I) X-ray powder diffraction (XRPD) of compound I maleate X-ray powder diffraction (XRPD) was obtained from a Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray radiation from copper at 1.054056 Å, K β A filter was used, (2) X-ray power was 30 KV, 15 mA, (3) the sample powder was dispersed on a zero background sample holder. The general measurement conditions for XRPD were: start angle 3 degrees, end angle 45 degrees; sampling 0.02 degrees; scan rate 2 degrees / min. The XRPD pattern is shown in Figure 1, and the XRPD data are shown in Table 1. [Table 1]

[0321] Differential Scanning Calorimetry (DSC) of Compound I Maleate (Form I) DSC was obtained from a TA Instruments Differential Scanning Calorimetry, Model Q200 equipped with an automatic sample feeder. The DSC instrument conditions were as follows: 30-300°C at 10°C / min; Tzero aluminum sample pan and lid; nitrogen gas flow rate of 50 mL / min. The DSC curve is shown in Figure 2. The DSC curve revealed a major endothermic event with an onset temperature of 202.9°C and a peak temperature of 211.0°C, which is believed to be the melting and decomposition temperature of the compound.

[0322] Thermogravimetric Analysis (TGA) of Compound I Maleate (Form I) TGA was obtained from a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for the TGA were: temperature gradient from 20°C to 600°C at 20°C / min; nitrogen purge, gas flow rate of 40 mL / min, followed by equilibration of purge flow rate; sample purge flow rate of 60 mL / min; platinum sample pan. The TGA curve is shown in Figure 3. A weight loss of about 0.7% was observed up to 150°C, which was believed to be associated with loss of moisture and residual solvent. The compound began to decompose significantly above 200°C.

[0323] Solubility of Compound I Maleate Salt (Form I) The solubility of Compound I maleate was measured at 25±1°C and 50±1°C. The general procedure for the solubility test at 25±1°C was as follows: 1) 3mL of each of the solvents listed in Table 1A was placed in an individual vial, 2) Compound I maleate was added to form a cloudy solution at 25°C, 3) an additional 15-20mg of Compound I maleate was added, 4) the mixture was stirred at 25±1°C for 48 hours, 5) the supernatant was filtered using a syringe filter, and 6) the saturated solution was diluted with MeOH and analyzed by HPLC. The general procedure for the solubility test at 50±1°C was as follows: That is, 1) 3 mL of each of the solvents listed in Table 1A was placed in an individual vial, 2) Compound I maleate was added to form a cloudy solution at 50° C., 3) an additional 20-25 mg of Compound I maleate was added, 4) the mixture was stirred at 50±1° C. for 24 hours, 5) the supernatant was filtered using a syringe filter heated to 50±1° C., and 6) the saturated solution was diluted with MeOH and analyzed by HPLC. The results are summarized in Table 1A. [Table 2]

[0324] Other crystalline salts Other crystalline salts of the compound of formula I have been discovered and prepared, including the HCl salt, the monosulfate salt, the hemisulfate salt, the mesylate salt, and the besylate salt.

[0325] Example 8 Preparation of salts of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (salts of compound II) Salts of Compound II were prepared according to the procedures in Table 2 below. These salts were analyzed by XRPD, DSC, and TGA (see Examples 9-15). [Table 3-1] [Table 3-2]

[0326] Example 9 Solid-State Characterization of Compound II Phosphate X-ray powder diffraction (XRPD) study of compound II phosphate Compound II phosphate was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray radiation of 1.054056 Å from copper, K β A filter was used, (2) X-ray power was 30 KV, 15 mA, (3) the sample powder was dispersed on a zero background sample holder. The general measurement conditions for XRPD were: start angle 3 degrees, end angle 45 degrees; sampling 0.02 degrees; scan rate 2 degrees / min.

[0327] The XRPD pattern of Compound II phosphate is shown in FIG. 4, and the XRPD data is shown in Table 3. [Table 4]

[0328] Differential scanning calorimetry (DSC) studies of compound II phosphate. Compound II phosphate was characterized by DSC. The DSC was obtained from a TA Instruments Differential Scanning Calorimetry, Model Q200 equipped with an automatic sample feeder. The DSC instrument conditions were as follows: 30-350°C at 10°C / min; Tzero aluminum sample pan and lid; and a nitrogen gas flow rate of 50 mL / min.

[0329] The DSC curve of Compound II phosphate is shown in Figure 5. The DSC curve reveals a major endothermic event with an onset temperature of 252.6°C and a peak temperature of 257.2°C, which is believed to be the melting / decomposition of the compound.

[0330] Thermogravimetric analysis (TGA) studies of compound II phosphate. Compound II phosphate was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for the TGA were: temperature gradient from 20°C to 600°C at 20°C / min; nitrogen purge, gas flow rate of 40 mL / min, followed by equilibration of purge flow rate; sample purge flow rate of 60 mL / min; platinum sample pan.

[0331] The TGA curve of compound II phosphate is shown in Figure 6. A weight loss of about 1.8% was observed up to 200°C, which was believed to be due to the loss of water or residual solvent. A significant weight loss was observed above 230°C, which was believed to be due to the decomposition of the compound.

[0332] Example 10 Solid-State Characterization of Compound II Maleate X-ray powder diffraction (XRPD) study of compound II maleic salt. Compound II maleate was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray radiation of 1.054056 Å from copper, K β A filter was used, (2) X-ray power was 30 KV, 15 mA, (3) the sample powder was dispersed on a zero background sample holder. The general measurement conditions for XRPD were: start angle 3 degrees, end angle 45 degrees; sampling 0.02 degrees; scan rate 2 degrees / min.

[0333] The XRPD pattern of Compound II maleate is shown in FIG. [Table 5]

[0334] Differential scanning calorimetry (DSC) studies of compound II maleate. Compound II maleate was characterized by DSC. The DSC was obtained from a TA Instruments Differential Scanning Calorimetry, Model Q200 equipped with an automatic sample feeder. The DSC instrument conditions were as follows: 30-300°C at 10°C / min; Tzero aluminum sample pan and lid; and a nitrogen gas flow rate of 50 mL / min.

[0335] The DSC curve of compound II maleate is shown in Figure 8. The DSC curve revealed two major endothermic events with an onset temperature of 183.4°C and a peak temperature of 194.8°C for the first event, followed by an onset temperature of 233.4°C and a peak temperature of 239.7°C for the second event.

[0336] Thermogravimetric analysis (TGA) studies of compound II maleate. Compound II maleate was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for the TGA were: temperature gradient from 20°C to 600°C at 20°C / min; nitrogen purge, gas flow rate of 40 mL / min, then equilibrated purge flow rate; sample purge flow rate of 60 mL / min; platinum sample pan.

[0337] The TGA curve of compound II maleate is shown in Figure 9. A weight loss of about 1.8% was observed up to 125°C, which was believed to be due to the loss of water or residual solvent. A significant weight loss was observed above 175°C, which was believed to be due to the decomposition of the compound.

[0338] Example 11 Solid-state characterization of Compound II hemisulfate X-ray powder diffraction (XRPD) study of compound II hemisulfate. Compound II hemisulfate was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray emission from copper at 1.054056 Å, K β A filter was used, (2) X-ray power was 30 KV, 15 mA, (3) the sample powder was dispersed on a zero background sample holder. The general measurement conditions for XRPD were: start angle 3 degrees, end angle 45 degrees; sampling 0.02 degrees; scan rate 2 degrees / min.

[0339] The XRPD pattern of Compound II hemisulfate is shown in FIG. 10 and the XRPD data is shown in Table 5. [Table 6]

[0340] Differential scanning calorimetry (DSC) studies of compound II hemisulfate. Compound II hemisulfate was characterized by DSC. The DSC was obtained from a TA Instruments Differential Scanning Calorimetry, Model Q200 equipped with an automatic sample feeder. The DSC instrument conditions were as follows: 30-350°C at 10°C / min; Tzero aluminum sample pan and lid; and a nitrogen gas flow rate of 50 mL / min.

[0341] The DSC curve of compound II hemisulfate is shown in Figure 11. The DSC curve reveals a major endothermic event with an onset temperature of 283.8°C and a peak temperature of 289.4°C, which is believed to be the melting / decomposition of the compound.

[0342] Thermogravimetric analysis (TGA) studies of compound II hemisulfate. Compound II hemisulfate was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for the TGA were: temperature gradient from 20°C to 600°C at 20°C / min; nitrogen purge, gas flow rate of 40 mL / min, followed by equilibration of purge flow rate; sample purge flow rate of 60 mL / min; platinum sample pan.

[0343] The TGA curve of compound II hemisulfate is shown in Figure 12. A weight loss of about 1.5% was observed up to 100°C, which was believed to be due to the loss of water or residual solvent. A significant weight loss was observed above 200°C, which was believed to be due to the decomposition of the compound.

[0344] Example 12 Solid-State Characterization of Compound II Hydrochloride X-ray powder diffraction (XRPD) study of compound II hydrochloride. Compound II hydrochloride was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray radiation of 1.054056 Å from copper, K β A filter was used, (2) X-ray power was 30 KV, 15 mA, (3) the sample powder was dispersed on a zero background sample holder. The general measurement conditions for XRPD were: start angle 3 degrees, end angle 45 degrees; sampling 0.02 degrees; scan rate 2 degrees / min.

[0345] The XRPD pattern of Compound II hydrochloride is shown in FIG. 13 and the XRPD data is shown in Table 6. [Table 7]

[0346] Differential scanning calorimetry (DSC) studies of compound II hydrochloride. Compound II hydrochloride was characterized by DSC. The DSC was obtained from a TA Instruments Differential Scanning Calorimetry, Model Q200 equipped with an automatic sample feeder. The DSC instrument conditions were as follows: 30-300°C at 10°C / min; Tzero aluminum sample pan and lid; and a nitrogen gas flow rate of 50 mL / min.

[0347] The DSC curve of Compound II hydrochloride is shown in Figure 14. The DSC curve reveals a major endothermic event with an onset temperature of 183.5°C and a peak temperature of 190.0°C, which is believed to be the melting / decomposition of the compound.

[0348] Thermogravimetric analysis (TGA) studies of compound II hydrochloride. Compound II hydrochloride was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for the TGA were: temperature gradient from 20°C to 600°C at 20°C / min; nitrogen purge, gas flow rate of 40 mL / min, then equilibrated purge flow rate; sample purge flow rate of 60 mL / min; platinum sample pan.

[0349] The TGA curve of Compound II hydrochloride is shown in Figure 15. A weight loss of about 5.9% was observed up to 200°C, which was believed to be due to the loss of water or residual solvent. A significant weight loss was observed above 200°C, which was believed to be due to the decomposition of the compound.

[0350] Example 13 Solid State Characterization of Compound II Salicylate X-ray powder diffraction (XRPD) studies of compound II salicylate. Compound II salicylate was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray radiation of 1.054056 Å from copper, K β A filter was used, (2) X-ray power was 30 KV, 15 mA, (3) the sample powder was dispersed on a zero background sample holder. The general measurement conditions for XRPD were: start angle 3 degrees, end angle 45 degrees; sampling 0.02 degrees; scan rate 2 degrees / min.

[0351] The XRPD pattern of Compound II salicylate is shown in FIG. 16 and the XRPD data is shown in Table 7. [Table 8]

[0352] Differential scanning calorimetry (DSC) studies of compound II salicylates. Compound II salicylate was characterized by DSC. The DSC was obtained from a TA Instruments Differential Scanning Calorimetry, Model Q200 equipped with an automatic sample feeder. The DSC instrument conditions were as follows: 30-300°C at 10°C / min; Tzero aluminum sample pan and lid; and a nitrogen gas flow rate of 50 mL / min.

[0353] The DSC curve for Compound II salicylate is shown in Figure 17. The DSC curve revealed three major endothermic events: a first endothermic event with an onset temperature of 176.0°C and a peak temperature of 181.7°C, a second endothermic event with an onset temperature of 209.9°C and a peak temperature of 224.9°C, and a third endothermic event with an onset temperature of 254.7°C and a peak temperature of 264.5°C.

[0354] Thermogravimetric analysis (TGA) studies of compound II salicylate. Compound II salicylate was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for the TGA were: temperature gradient from 20°C to 600°C at 20°C / min; nitrogen purge, gas flow rate of 40 mL / min, then equilibrated purge flow rate; sample purge flow rate of 60 mL / min; platinum sample pan.

[0355] The TGA curve of compound II salicylate is shown in Figure 18. In the first step, a weight loss of about 8.1% was observed up to 250°C. A significant weight loss was observed above 300°C, which was believed to be due to the decomposition of the compound.

[0356] Example 14 Solid-state characterization of Compound II mesylate X-ray powder diffraction (XRPD) study of compound II mesylate. Compound II mesylate was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray radiation from copper at 1.054056 Å, K β A filter was used, (2) X-ray power was 30 KV, 15 mA, (3) the sample powder was dispersed on a zero background sample holder. The general measurement conditions for XRPD were: start angle 3 degrees, end angle 45 degrees; sampling 0.02 degrees; scan rate 2 degrees / min.

[0357] The XRPD pattern of Compound II mesylate is shown in FIG. 19 and the XRPD data is shown in Table 8. [Table 9]

[0358] Differential scanning calorimetry (DSC) studies of compound II mesylate. Compound II mesylate was characterized by DSC. The DSC was obtained from a TA Instruments Differential Scanning Calorimetry, Model Q200 equipped with an automatic sample feeder. The DSC instrument conditions were as follows: 30-300 °C at 10 °C / min; Tzero aluminum sample pan and lid; and a nitrogen gas flow rate of 50 mL / min.

[0359] The DSC curve of Compound II mesylate is shown in Figure 20. The DSC curve reveals a major endothermic event with an onset temperature of 166.3°C and a peak temperature of 174.8°C, which is believed to be the melting / decomposition of the compound.

[0360] Thermogravimetric analysis (TGA) studies of compound II mesylate. Compound II mesylate was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for the TGA were: temperature gradient from 20°C to 600°C at 20°C / min; nitrogen purge, gas flow rate of 40 mL / min, followed by equilibration of purge flow rate; sample purge flow rate of 60 mL / min; platinum sample pan.

[0361] The TGA curve of Compound II mesylate is shown in Figure 21. A weight loss of about 2.3% was observed up to 100°C, which was believed to be due to the loss of water or residual solvent. A significant weight loss was observed above 200°C, which was believed to be due to the decomposition of the compound.

[0362] Example 15 Solid-State Characterization of Compound II Esylate Salt X-ray powder diffraction (XRPD) study of compound II esylate salt. Compound II esylate was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray radiation of 1.054056 Å from copper, K β A filter was used, (2) X-ray power was 30 KV, 15 mA, (3) the sample powder was dispersed on a zero background sample holder. The general measurement conditions for XRPD were: start angle 3 degrees, end angle 45 degrees; sampling 0.02 degrees; scan rate 2 degrees / min.

[0363] The XRPD pattern of Compound II esylate salt is shown in FIG. 22 and the XRPD data is shown in Table 9. [Table 10]

[0364] Differential scanning calorimetry (DSC) studies of compound II esylate salt. Compound II esylate was characterized by DSC. The DSC was obtained from a TA Instruments Differential Scanning Calorimetry, Model Q200 equipped with an automatic sample feeder. The DSC instrument conditions were as follows: 30-300°C at 10°C / min; Tzero aluminum sample pan and lid; and a nitrogen gas flow rate of 50 mL / min.

[0365] The DSC curve of Compound II esylate salt is shown in Figure 23. The DSC curve reveals a major endothermic event with an onset temperature of 180.4°C and a peak temperature of 187.7°C, which is believed to be the melting / decomposition of the compound.

[0366] Thermogravimetric analysis (TGA) studies of compound II esylate salt. Compound II esylate was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for the TGA were: temperature gradient from 20°C to 600°C at 20°C / min; nitrogen purge, gas flow rate of 40 mL / min, followed by equilibration of purge flow rate; sample purge flow rate of 60 mL / min; platinum sample pan.

[0367] The TGA curve of Compound II esylate is shown in Figure 24. A weight loss of about 1.6% was observed up to 100°C, which was considered to be due to the loss of water or residual solvent. A significant weight loss was observed above 200°C, which was considered to be due to the decomposition of the compound.

[0368] Example 16 Preparation of other crystalline forms of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate (Compound I maleate, Forms II-V) The experimental procedures for the formation of Compound I maleate salt forms II, III, IV, and V are summarized in Table 10. [Table 11]

[0369] Example 17 Solid State Characterization of Compound I Maleate, Form II X-Ray Powder Diffraction (XRPD) of Compound I Maleate, Form II X-ray powder diffraction (XRPD) was obtained from a Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray radiation from copper at 1.054056 Å, K βA filter was used, (2) X-ray power was 30 KV, 15 mA, (3) the sample powder was dispersed on a zero background sample holder. The general measurement conditions for XRPD were: start angle 3 degrees, end angle 45 degrees; sampling 0.02 degrees; scan rate 2 degrees / min.

[0370] The XRPD pattern of Form II of Compound I maleate salt is shown in FIG. 25, and the XRPD data is shown in Table 11. [Table 12]

[0371] Example 18 Solid State Characterization of Compound I Maleate, Form III X-ray powder diffraction (XRPD) was obtained from a Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray radiation from copper at 1.054056 Å, K β A filter was used, (2) X-ray power was 30 KV, 15 mA, (3) the sample powder was dispersed on a zero background sample holder. The general measurement conditions for XRPD were: start angle 3 degrees, end angle 45 degrees; sampling 0.02 degrees; scan rate 2 degrees / min.

[0372] The XRPD pattern of Form III of the compound I maleate salt is shown in FIG. 26, and the XRPD data is shown in Table 12. [Table 13]

[0373] Differential scanning calorimetry (DSC) study of compound I maleate, form III. Form III of the compound I maleate salt was characterized by DSC. The DSC was obtained from a TA Instruments Differential Scanning Calorimetry, Model Q200 equipped with an automatic sample feeder. The DSC instrument conditions were as follows: 30-300°C at 10°C / min; Tzero aluminum sample pan and lid; and a nitrogen gas flow rate of 50 mL / min.

[0374] The DSC curve of Compound I maleate, Form III, is shown in Figure 27. The DSC curve revealed two endothermic events: a first endothermic event with an onset temperature of 143.9°C and a peak temperature of 165.4°C, and a second endothermic event with an onset temperature of 186.3°C and a peak temperature of 195.4°C.

[0375] Thermogravimetric analysis (TGA) study of compound I maleate, form III. Compound I maleate Form III was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for the TGA were: temperature gradient from 20° C. to 600° C. at 20° C. / min; nitrogen purge, gas flow rate of 40 mL / min, followed by equilibration of purge flow rate; sample purge flow rate of 60 mL / min; platinum sample pan.

[0376] The TGA curve of Compound I maleate salt, Form III, is shown in FIG.

[0377] Example 19 Solid State Characterization of Compound I Maleate, Form IV X-ray powder diffraction (XRPD) was obtained from a Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray radiation from copper at 1.054056 Å, K βA filter was used, (2) X-ray power was 30 KV, 15 mA, (3) the sample powder was dispersed on a zero background sample holder. The general measurement conditions for XRPD were: start angle 3 degrees, end angle 45 degrees; sampling 0.02 degrees; scan rate 2 degrees / min.

[0378] The XRPD pattern of Form IV of Compound I maleate salt is shown in FIG. 29, and the XRPD data is shown in Table 13. [Table 14]

[0379] Differential scanning calorimetry (DSC) study of compound I maleate, form IV. Form IV of compound I maleate salt was characterized by DSC. The DSC was obtained from a TA Instruments Differential Scanning Calorimetry, Model Q200 equipped with an automatic sample feeder. The DSC instrument conditions were as follows: 30-300°C at 10°C / min; Tzero aluminum sample pan and lid; and a nitrogen gas flow rate of 50 mL / min.

[0380] The DSC curve of Compound I maleate, Form IV is shown in Figure 30. The DSC curve revealed two endothermic events: a first endothermic event with an onset temperature of 145.7°C and a peak temperature of 152.1°C, and a second endothermic event with an onset temperature of 188.3°C and a peak temperature of 202.6°C.

[0381] Thermogravimetric analysis (TGA) study of compound I maleate, form IV. Form IV of compound I maleate salt was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for the TGA were: temperature gradient from 20° C. to 600° C. at 20° C. / min; nitrogen purge, gas flow rate of 40 mL / min, followed by equilibration of purge flow rate; sample purge flow rate of 60 mL / min; platinum sample pan.

[0382] The TGA curve of Compound I maleate salt, Form IV, is shown in FIG.

[0383] Example 20 Solid State Characterization of Compound I Maleate, Form V X-ray powder diffraction (XRPD) was obtained from a Rigaku MiniFlex X-ray Powder Diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray radiation from copper at 1.054056 Å, K β A filter was used, (2) X-ray power was 30 KV, 15 mA, (3) the sample powder was dispersed on a zero background sample holder. The general measurement conditions for XRPD were: start angle 3 degrees, end angle 45 degrees; sampling 0.02 degrees; scan rate 2 degrees / min.

[0384] The XRPD pattern of Form V of the compound I maleate salt is shown in FIG. 32 and the XRPD data is shown in Table 14. [Table 15]

[0385] Differential scanning calorimetry (DSC) study of compound I maleate, form V. Form V of the compound I maleate salt was characterized by DSC. The DSC was obtained from a TA Instruments Differential Scanning Calorimetry, Model Q200 equipped with an automatic sample feeder. The DSC instrument conditions were as follows: 30-300°C at 10°C / min; Tzero aluminum sample pan and lid; and a nitrogen gas flow rate of 50 mL / min.

[0386] The DSC curve of Compound I maleate, Form V is shown in Figure 33. The DSC curve revealed an endothermic event with an onset temperature of 189.1°C and a peak temperature of 200.1°C.

[0387] Thermogravimetric analysis (TGA) study of compound I maleate, form V Compound I maleate Form V was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for the TGA were: temperature gradient from 20° C. to 600° C. at 20° C. / min; nitrogen purge, gas flow rate of 40 mL / min, followed by equilibration of purge flow rate; sample purge flow rate of 60 mL / min; platinum sample pan.

[0388] The TGA curve of Compound I maleate salt, Form V is shown in FIG.

[0389] Example A Axl autophosphorylation assay Autophosphorylation of Axl was performed by incubating recombinant Axl protein (Life Technologies, PV4275) in a buffer containing 50 mM Tris (pH 7.5), 0.2 mg / ml Axl, 5 mM ATP, 20 mM MgCl2, and 2 mM DTT for 1 h at room temperature.

[0390] TAM enzyme assay Kinase assay buffer contained 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% NP-40, and 2 mM DTT. 0.1 ul of DMSO solution of test compound was transferred from compound plate to a white 384-well assay plate (Greiner LUMITRAC plate). Final concentration of DMSO was 1.25%. 5.1 nM phosphorylated Axl, or 0.0625 nM c-Mer (Carna Biosciences, 08-108), or 0.366 nM Tyro3 (Life Technologies, PR7480A) were prepared in assay buffer. A 1 mM stock solution of peptide substrate Biotin-EQEDEPEGDYFEWLE-amide SEQ ID NO:1 (Quality Controlled Biochemicals, MA) was diluted to 1 uM in assay buffer containing 2000 uM ATP. 4ul of enzyme solution (or assay buffer for enzyme blank test) was added to the appropriate wells of each plate, followed by 4ul / well of substrate solution to initiate the reaction. Plates were protected from light and incubated at room temperature for 60 minutes. The reaction was stopped by adding 4ul of detection solution containing 50mM Tris-HCl (pH 7.8), 150mM NaCl, 0.05% BSA, 45mM EDTA, 180nM SA-APC (PerkinElmer, CR130-100), and 3nM Eu-W1024 anti-phosphorylated tyrosine PY20 (PerkinElmer, AD0067). The plate was incubated at room temperature for 1 hour and HTRF (homogeneous time resolved fluorescence) signal was measured on a PHERAstar FS plate reader (BMG labtech). The percentage of inhibition was calculated for each concentration and IC was determined from curve fitting using GraphPad Prism software. 50 derived the value.

[0391] The compounds of formula I and II have been found to be inhibitors of one or more of AXL, MER, and TYRO3. IC for the trifluoroacetate salts of the compounds of formula I and II 50The data are disclosed in U.S. Patent Application Serial No. 15 / 469,975 and are presented below in Table 15. The symbol "†" indicates an IC of ≦5 nM. 50 and "††" indicates IC >5 nM but ≤10 nM. 50 and "†††" indicates IC >10 nM but ≤100 nM. 50 Shows. [Table 16]

[0392] Example B. Generation of BAF3-AXL, BAF3-MER, and BAF3-TYRO3 Cells and Cell Proliferation Assays The cytoplasmic domain of AXL, MER, or TYRO3 fused with a dimerization sequence and an HA tag is cloned into the pMSCV vector with a puromycin resistance marker to generate three constructs (pMSCV-AXL, pMSCV-MER, and pMSCV-TYRO3). BAF3 cells are transfected with the three constructs individually by electroporation. Single clones that are IL3-independent and puromycin-resistant are selected and characterized. Cells with stable expression of AXL, MER, or TYRO3 are selected and designated BAF3-AXL, BAF3-MER, and BAF3-TYRO3 cells.

[0393] BAF3, BAF3-AXL, BAF3-MER, or BAF3-TYRO3 cell lines are maintained in RPMI1640 (Gibco / Life Technologies, Carlsbad, CA) containing 10% FBS. To measure the effect of test compounds on cell viability, 1000 cells / well are seeded in 384-well tissue culture plates in growth medium containing serial dilutions of compound or DMSO alone and incubated at 37°C under 5% CO2 for 48 hours, and cell viability is measured by ATP assay (CellTiter-Glo Assay, Promega) according to the manufacturer's procedure. Data are converted to percent inhibition relative to DMSO control and expressed as IC 50 Curves are curve fitted using GraphPad Prism software.

[0394] Example C BaF3-AXL ELISA and BaF3-MER ELISA BaF3-AXL or BaF3-MER cells are maintained in RPMI medium containing 10% FBS and puromycin (1 μg / ml, Gibco / Life Technologies, Carlsbad, Calif.). To measure the effect of test compounds on phosphorylated AXL or phosphorylated MER, cells were plated (5×10) in V-bottom polypropylene plates (Greiner bio-one) in the presence or absence of test compounds diluted in medium. 4 Cells are incubated for 1 hour at 37°C under 5% CO2 (cells / well). Cells are harvested by centrifugation and lysed in 110 μl ice-cold lysis buffer (Cell Signaling) containing protease and phosphatase inhibitors (Halts PI, ThermoFisher) for 30 minutes on ice. Cell lysates are stored at -80°C and ELISA is performed. ELISA plates are prepared by incubating Costar plates with anti-HA antibody (1 μg / ml) for 1 hour at room temperature. The plates are washed and blocked with PBS containing 3% BSA. Cell lysates are added to the ELISA plate and incubated overnight at 4°C. The plates are washed and incubated with LANCE Eu-W1024 anti-phosphorylated tyrosine antibody (PY-20) (PerkinElmer) in DELFIA assay buffer (PerkinElmer) for 1 hour and read on a Pherastar (BMG Labtech). Data were converted to percent inhibition relative to the DMSO control and GraphPad Prism was used to calculate IC by fitting a curve of percent inhibition versus the logarithm of inhibitor concentration. 50 Determine.

[0395] Example D H1299 phosphorylated AXL ELISA H1299 cells (ATCC), a human non-small cell lung cancer cell line expressing Axl, are maintained in medium RPMI containing 10% FBS (Gibco / Life Technologies, Carlsbad, CA). To measure the effect of test compounds on phosphorylated AXL, the cells are seeded (30,000 cells / well) in 96-well tissue culture plates (Costar) and incubated overnight at 37°C under 5% CO2. Appropriate concentrations of compounds are added and incubated for 1 hour at 37°C under 5% CO2. rhGas6 (R&D Systems, 6 μg / ml) is added to each well. The plate is incubated for 15 minutes at 37°C under 5% CO2. Cells are harvested and lysed in 110 μL of ice-cold lysis buffer (Cell Signaling) containing protease and phosphatase inhibitors (Halts PI, ThermoFisher). Lysates are incubated on ice for 1 hour, stored at -80°C, and ELISA is performed. ELISA plates are prepared by incubating Costar plates with anti-HA antibody (1 μg / ml) for 1 hour at room temperature. The plates are washed and blocked with PBS containing 3% BSA. Cell lysates are added to the ELISA plates and incubated overnight at 4° C. The plates are washed and incubated with LANCE Eu-W1024 anti-phosphorylated tyrosine antibody (PY-20) (PerkinElmer) in DELFIA assay buffer (PerkinElmer) for 1 hour and read on a Pherastar (BMG Labtech). Data are converted to percent inhibition relative to DMSO control and ICs are calculated by fitting the curve of percent inhibition versus log inhibitor concentration using GraphPad Prism. 50 Determine.

[0396] Example E Whole blood H1299 phosphorylated AXL ELISA H1299 cells (ATCC) are maintained in medium RPMI (Gibco / Life Technologies, Carlsbad, CA) containing 10% FBS. To measure the effect of test compounds on phosphorylated AXL, the cells are seeded (30000 cells / well) in 96-well tissue culture plates (Costar) and incubated overnight at 37°C under 5% CO2. Blood from normal donors is mixed with the test compounds for 1 hour. The medium is removed from the H1299 cells and blood containing the compounds is added to each well. After 1 hour of incubation at 37°C under 5% CO2, rh-Gas6 (4 μg / ml, R&D Systems) is added to each well. The plate is incubated for 15 minutes at 37°C under 5% CO2. The cells are harvested and lysed in 110 uL of ice-cold lysis buffer (Cell Signaling) containing protease and phosphatase inhibitors (Halts PI, ThermoFisher) on ice for 1 hour. Plates are stored at -80°C and ELISA is performed. ELISA plates are prepared by incubating Costar plates with anti-HA antibody (1ug / ml) for 1 hour at room temperature. The plates are washed and blocked with PBS containing 3% BSA. Cell lysates are added to the ELISA plate and incubated overnight at 4°C. The plates are washed and incubated with LANCE Eu-W1024 anti-phosphorylated tyrosine antibody (PY-20) (PerkinElmer) in DELFIA assay buffer (PerkinElmer) for 1 hour and read on a Pherastar (BMG Labtech). Data are converted to percent inhibition relative to DMSO control and ICs are calculated by fitting the curve of percent inhibition versus log of inhibitor concentration using GraphPad Prism. 50 Determine.

[0397] Example F G361 phosphorylated Akt CellInsight ELISA G361 cells (ATCC), a human melanoma cell line expressing Mer, are maintained in RPMI medium (Gibco / Life Technologies, Carlsbad, CA) containing 10% FBS. To measure the effect of test compounds on the MER signaling pathway, the cells were plated in 96-well CellBind surface plates (Corning) at 2 × 10 cells in a volume of 100 μL. 4 Seed cells / well and incubate overnight at 37°C under 5% CO2. Add 20 μL of the appropriate concentration of test compound to the cells and incubate for 1 hour. Add rhGas6 (4 μg / ml, R&D Systems) to each well and incubate for 20 minutes. Fix cells by adding 50 uL of 4% paraformaldehyde (Electron Microscopy Sciences) in PBS (Corning) for 30 minutes at room temperature. Wash plates and incubate with 50 uL of 0.2% tritonX-100 (Sigma) in PBS for 10 minutes at room temperature. Wash plates and incubate with 100 uL of blocking buffer (0.1% BSA in PBS) for 30 minutes. Plates are washed and incubated overnight at 4° C. with phosphorylated AKT (Ser473) (D9E) rabbit mAb (Cell Signaling) diluted in 0.1% BSA (1:300 dilution). Plates are washed and incubated with 50 uL of Alexaflour 488 goat anti-rabbit IgG (H+L) F(ab') 2 Incubate with fragments (Molecular Probes, 1:1000 dilution) and Hoechst 33342 (ThermoFisher, 1:2000 dilution) in PBS for 2 hours at room temperature. Plates are washed with PBS and read on a CellInsight CX5 (ThermoFisher).

[0398] In addition to those described herein, various modifications of the present invention will be apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. Each reference, including all patents, patent applications, and publications cited in this application, is hereby incorporated by reference in its entirety. The present application also includes the following aspects. [Aspect 1] A salt which is N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate. [Aspect 2] The salt of embodiment 1, which is a salt having a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide to maleic acid. [Aspect 3] The salt according to embodiment 1, which is crystalline. [Aspect 4] 2. A substantially isolated salt according to embodiment 1. [Aspect 5] 2. The salt according to embodiment 1, characterized by a DSC curve having an endothermic peak at about 211° C. [Aspect 6] The salt according to embodiment 1, whose DSC curve is substantially as shown in FIG. [Aspect 7] The salt according to embodiment 1, whose TGA curve is substantially as shown in FIG. [Aspect 8] The salt according to embodiment 1, having at least one XRPD peak selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5° in terms of 2θ. [Aspect 9] 2. The salt of embodiment 1, having at least two XRPD peaks selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5° in terms of 2θ. [Aspect 10] 2. The salt of embodiment 1, having at least three XRPD peaks selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5° in terms of 2θ. [Aspect 11] 2. The salt of embodiment 1, having at least four XRPD peaks selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5° in terms of 2θ. [Aspect 12] 2. The salt according to embodiment 1, having the following XRPD peaks, expressed in terms of 2θ: about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°. [Aspect 13] The salt according to embodiment 1, having an XRPD profile substantially as shown in FIG. [Aspect 14] A salt which is N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate. [Aspect 15] The salt according to embodiment 14, which is a salt having a stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to sulfuric acid of 1:0.5. [Aspect 16] 15. The salt according to embodiment 14, which is crystalline. [Aspect 17] 15. A substantially isolated salt according to embodiment 14. [Aspect 18] 15. The salt according to embodiment 14, characterized by a DSC curve having an endothermic peak at about 289.4°C. [Aspect 19] The salt according to embodiment 14, whose DSC curve is substantially as shown in FIG. [Aspect 20] The salt according to embodiment 14, whose TGA curve is substantially as shown in FIG. [Aspect 21] 15. The salt according to embodiment 14, having at least one XRPD peak selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9° in terms of 2θ. [Aspect 22] 15. The salt according to embodiment 14, having at least two XRPD peaks selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9° in terms of 2θ. [Aspect 23] 15. The salt according to embodiment 14, having at least three XRPD peaks selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9° in terms of 2θ. [Aspect 24] 15. The salt according to embodiment 14, having at least four XRPD peaks selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9° in terms of 2θ. [Aspect 25] 15. The salt according to embodiment 14, having the following XRPD peaks, expressed in terms of 2θ: about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9°. [Aspect 26] The salt according to embodiment 14, having an XRPD profile substantially as shown in FIG. 10. [Aspect 27] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide phosphate, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hydrochloride, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide salicylate, N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide methanesulfonate, and N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide ethanesulfonate A salt selected from: [Aspect 28] A pharmaceutical composition comprising the salt according to any one of aspects 1 to 27 and a pharma- ceutically acceptable carrier. [Aspect 29] A method of inhibiting a TAM kinase, the method comprising contacting the TAM kinase with a salt according to any one of aspects 1 to 27. [Aspect 30] A method for inhibiting AXL kinase and MER kinase, the method comprising contacting the AXL kinase and MER kinase with a salt according to any one of aspects 1 to 27. [Aspect 31] A method of treating cancer in a patient, the method comprising administering to said patient a therapeutically effective amount of a salt according to any one of aspects 1 to 27. [Aspect 32] 32. The method of embodiment 31, wherein the cancer is selected from hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin's lymphoma or non-Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, hairy cell lymphoma, Burkitt's lymphoma, glioblastoma, melanoma, and rhabdomyosarcoma. [Aspect 33] The method of embodiment 31, wherein the cancer is lung cancer, prostate cancer, colon cancer, breast cancer, melanoma, renal cell carcinoma, multiple myeloma, gastric cancer, or rhabdomyosarcoma. [Aspect 34] A method for preparing the salt according to embodiment 1, comprising the step of:

change

change

Claims

1. A pharmaceutical combination for the treatment of cancer comprising a salt which is N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate and a further therapeutic agent, wherein said salt and said further therapeutic agent are administered simultaneously or sequentially in a single dosage form or in separate dosage forms to a patient in need of said treatment of cancer; the additional therapeutic agent being i) antiviral agents, chemotherapeutic or other anticancer agents, immune enhancing agents, immunosuppressants, radiation, antitumor, antiviral vaccines, cytokine therapy agents, and tyrosine kinase inhibitors; ii) an inhibitor of an immune checkpoint molecule selected from an anti-PD1 antibody, an anti-PD-L1 antibody, and an anti-CTLA-4 antibody; Selected from: The combination drug.

2. 2. The combination pharmaceutical of claim 1, wherein the cancer is selected from hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin's lymphoma or non-Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, hairy cell lymphoma, Burkitt's lymphoma, glioblastoma, melanoma, and rhabdomyosarcoma.

3. The pharmaceutical combination of claim 1, wherein the cancer is lung cancer, prostate cancer, colon cancer, breast cancer, melanoma, renal cell carcinoma, multiple myeloma, gastric cancer, or rhabdomyosarcoma.

4. The pharmaceutical combination according to claim 1, wherein the cancer is head and neck cancer.

5. The pharmaceutical combination according to any one of claims 1 to 4, wherein the further therapeutic agent is selected from an antiviral agent, a chemotherapeutic agent or other anticancer agent, an immunoenhancing agent, an immunosuppressant, radiation, an antitumor, an antiviral vaccine, a cytokine therapy agent, and a tyrosine kinase inhibitor.

6. The combination pharmaceutical according to any one of claims 1 to 4, wherein the further therapeutic agent is an inhibitor of an immune checkpoint molecule selected from an anti-PD1 antibody, an anti-PD-L1 antibody, and an anti-CTLA-4 antibody.

7. The pharmaceutical combination according to any one of claims 1 to 6, wherein the salt has a stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide to maleic acid of 1:

1.

8. The pharmaceutical combination according to any one of claims 1 to 7, wherein the salt is a crystalline salt.

9. 9. The pharmaceutical combination according to claim 8, wherein the crystalline salt is characterized by a DSC curve having an endothermic peak at 211° C.±3° C.

10. The crystalline salt has a DSC curve as shown in FIG. The pharmaceutical combination according to claim 8 or 9, which is represented by the formula:

11. The crystalline salt has a TGA curve shown in FIG. The pharmaceutical combination according to any one of claims 8 to 10, which is represented by:

12. The crystalline salt has an XRPD profile as shown in FIG. The pharmaceutical combination according to any one of claims 8 to 11, which is represented by:

Images